医薬品開発業務受託機関（CRO）サービス市場規模、シェア、動向、2031年までの世界予測

医薬品開発業務受託機関（CRO）サービス市場は、予測期間中の年平均成長率（CAGR）が8.6%で、2026年の930億2,000万米ドルから2031年には1,403億2,000万米ドルに達するとMarketsandMarketsでは予測しています。

市場成長に貢献する主な要因としては、細胞・遺伝子治療のパイプラインの拡大と精密医療への注目の高まりが挙げられます。これらの要因により、スポンサーは、複雑な設計、ゲノムスクリーニング、カスタマイズ可能なロジスティクス、社内での実施が困難な必須の長期フォローアップ機能に対応できるCROパートナーを求めるようになると予想されます。精密医療プログラムでは患者コホートが細分化され、登録期間が短縮されるため、統合されたCROラボネットワークとグローバルな施設カバレッジが、タイムラインとデータ品質にとって決定的に重要になります。規制当局と支払機関が堅牢でリアルタイムのエビデンスを要求するにつれ、スポンサーは、開発リスクを軽減するために、高度なラボ、データサイエンス、およびRWE機能を備えた臨床業務を提供するCROへの依存度を高めています。

調査概要

本調査レポートは、CROサービス市場を、タイプ（臨床研究サービス、初期開発サービス、ラボサービス、コンサルティングサービス、データ管理サービス）、モダリティ（低分子医薬品、バイオ医薬品、バイオシミラー、医療機器）、提供モデル（フルサービスアウトソーシング（FSO）モデル、機能サービスプロバイダー（FSP）モデル、ハイブリッドモデル）、エンドユーザー（製薬・バイオ医薬品企業、医療機器企業、学術機関）、地域（北米、欧州、アジア太平洋、ラテンアメリカ、中東、アフリカ）別に分類しています。レポートでは、CROサービス市場の成長に影響を与える要因（推進要因、阻害要因、課題、機会など）に関する詳細な情報を提供しています。

主要企業の徹底的な分析により、各社の事業概要、サービス、主要戦略、提携、パートナーシップ、契約に関する洞察が得られています。CROサービス市場における最近の動向としては、新製品発売、提携、パートナーシップ、買収などが挙げられます。

本レポートを購入する主なメリット

本レポートは、CROサービス市場全体およびそのサブセグメントの収益に関する最も正確な概算値を提供することで、市場リーダーや新規参入企業を支援します。また、関係者が競争環境をより深く理解し、より効果的な事業展開と適切な市場参入戦略の策定に役立つ洞察を得るのにも役立ちます。さらに、市場の動向を把握し、主要な市場推進要因、機会、課題に関する情報を提供します。

本レポートは、以下のポイントに関する洞察を提供します。

• 市場の成長に影響を与える主要な推進要因（分散型治験への注目の高まり、治験の複雑化と規模の拡大、CROが提供するサービスの柔軟性）、機会（患者プールの多様性に関する規制上の注目）、および課題（患者維持の課題、サイバーセキュリティ／知的財産に関する懸念）の分析。
• サービス開発／イノベーション：CROサービス市場における新規サービスに関する詳細な洞察。
• 市場開発：有望な市場に関する包括的な情報 ― 本レポートは、様々な地域における市場を分析しています。
• 市場の多様化：CROサービス市場における新規サービス、未開拓地域、最新動向、投資に関する包括的な情報。
• 競合評価：IQVIA Inc.（米国）、ICON Plc（アイルランド）、Medpace（米国）、Laboratory Corporation of America Holdings（LabCorp）（米国）、Thermo Fisher Scientific Inc.（米国）、Fortrea, Inc.（米国）などの主要企業の市場シェア、成長戦略、サービス提供内容を詳細に評価。主要企業に関する詳細な分析を実施し、主要戦略、サービス開始、買収、提携、契約、協力、事業拡大、その他の最新動向、投資・資金調達活動、ブランド／サービス比較分析、CROサービス市場におけるベンダー評価および財務指標に関する洞察を提供。

Report Description

The contract research organization (CRO) services market is expected to reach USD 140.32 billion in 2031 from USD 93.02 billion in 2026, at a CAGR of 8.6% during the forecast period. The key factors contributing to market growth include the expanding pipeline of cell & gene therapies and the growing focus on precision medicine. These factors are expected to drive sponsors toward CRO partners that can handle complex designs, genomic screening, customizable logistics, and mandatory long-term follow-up capabilities that are challenging to implement in-house. Precision programs fragment patient cohorts and shorten enrollment windows, making integrated CRO-lab networks and global site coverage decisive for timelines and data quality. As regulators and payers demand robust, real-time evidence, sponsors increasingly depend on CROs that offer clinical operations with advanced lab, data science, and RWE capabilities to de-risk development.

By service type, the early phase development services segment accounted for the second-largest share of the CRO services market in 2025.

Based on service type, the CRO services market is segmented into clinical research, early-phase development, laboratory, consulting, and data management services. In 2025, the early phase development services segment accounted for the second-largest share of the market. The current pipeline is focused on developing novel biologics, CGT, and targeted modalities that require specialized toxicology, DMPK, bioanalysis, and safety pharmacology, which several sponsors prefer to outsource to reach the IND (investigational new drug) stage faster.

By end user, the pharmaceutical & biopharmaceutical companies accounted for the largest share in the CRO services market in 2025.

Based on end user, the CRO services market is segmented into pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes. In 2025, the pharmaceutical & biopharmaceutical companies segment accounted for the largest share of the CRO services market. The large share of this end-user segment can be attributed to the large number of drug pipeline products of pharma and biotech companies. Moreover, CROs deliver speed, scale, and flexible cost bases, attracting end users.

By region, North America accounted for the largest share of the market in 2025.

In 2025, North America held the largest share of the global CRO services market, driven by the presence of well-established pharmaceutical and biotechnology industries, which drive significant demand for outsourced research and development services. Additionally, a vast network of clinical sites, hospitals, and specialized facilities provides an ideal infrastructure for conducting large-scale clinical trials in the region. Additionally, the rapid adoption of digital health solutions and decentralized trial models in the US, a significant contributor to the region’s substantial share, is further boosting CRO demand, as sponsors seek innovative ways to improve patient recruitment and retention.

List of Companies Profiled in the Report:

• IQVIA Inc. (US)
• ICON plc (Ireland)
• Thermo Fisher Scientific Inc. (US)
• Laboratory Corporation of America Holdings (LabCorp) (US)
• Fortrea, Inc. (US)
• Syneos Health (US)
• WuXi AppTec (China)
• Charles River Laboratories (US)
• PAREXEL International Corporation (US)
• Pharmaron (China)
• Medpace (US)
• SGS SA (Switzerland), Frontage Labs (US)
• Eurofins Scientific (Luxembourg)
• BioAgile (India)
• Firma Clinical Research (US)
• Acculab Life Sciences (US)
• Novotech (Australia)
• KCR S.A. (US)
• Linical (Japan)
• Advanced Clinical (US)
• Allucent (US)
• Clinical Trial Service (Netherlands)
• Guires Inc. (Pepgra Healthcare Pvt. Ltd.) (UK)
• Worldwide Clinical Trials (US)
• CTI Clinical Trial And Consulting (US)

Research Coverage

This research report categorizes the CRO services market by type (clinical research services, early-phase development services, laboratory services, consulting services, and data management services), modality (small molecules, biologics, biosimilars, medical devices), delivery model (Full-service outsourcing (FSO) model, Functional service provider (FSP) model, Hybrid model), end user (pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes), and region (North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa). The report covers detailed information regarding the leading factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the CRO services market. A thorough analysis of the key industry players has provided insights into their business overview, services, key strategies, collaborations, partnerships, and agreements. New launches, collaborations, partnerships, and acquisitions are the recent developments associated with the CRO services market.

Key Benefits of Buying the Report

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall CRO services market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business more effectively and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on key market drivers, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (increasing focus on decentralized trials, rising complexity and volume of trials, service flexibility offered by CROs), opportunities (regulatory focus on patient pool diversity), and challenges (challenges of patient retention and cybersecurity/intellectual property concerns) influencing the growth of the market.
• Service Development/Innovation: Detailed insights on newly launched services of the CRO services market
• Market Development: Comprehensive information about lucrative markets – the report analyzes the market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the CRO services market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of key players, including IQVIA Inc. (US), ICON Plc (Ireland), Medpace (US), Laboratory Corporation of America Holdings (LabCorp) (US), Thermo Fisher Scientific Inc. (US), and Fortrea, Inc. (US). A detailed analysis of the key industry players has been conducted to provide insights into their key strategies, service launches, acquisitions, partnerships, agreements, collaborations, expansions, other recent developments, investment and funding activities, brand/service comparative analysis, and vendor valuation and financial metrics of the CRO services market

Table of Contents

1 INTRODUCTION 57
1.1 STUDY OBJECTIVES 57
1.2 MARKET DEFINITION 57
1.3 STUDY SCOPE 58
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 58
1.3.2 INCLUSIONS AND EXCLUSIONS 59
1.3.3 YEARS CONSIDERED 60
1.3.4 CURRENCY CONSIDERED 61
1.4 STAKEHOLDERS 61
1.5 SUMMARY OF CHANGES 61
2 EXECUTIVE SUMMARY 63
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 63
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 64
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 65
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 66
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 67
3 PREMIUM INSIGHTS 69
3.1 GLOBAL CRO SERVICES MARKET SNAPSHOT 69
3.2 NORTH AMERICA: CRO SERVICES MARKET, BY MODALITY AND COUNTRY, 2024 70
3.3 CRO SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 71
4 MARKET OVERVIEW 72
4.1 INTRODUCTION 72
4.2 MARKET DYNAMICS 72
4.2.1 DRIVERS 73
4.2.1.1 Rising trial volume and complexity 73
4.2.1.2 Growing focus on decentralized/patient-centric trials 74
4.2.1.3 Service flexibility offered by CROs 74
4.2.1.4 Technological integrations 75
4.2.1.5 Growing R&D investments and presence of a robust clinical pipeline 76
4.2.2 OPPORTUNITIES 77
4.2.2.1 Growing regulatory stringency on the diversity of the patient pool 77
4.2.2.2 Risk-based monitoring (RBM) and risk-based quality management as a service 77
4.2.2.3 Offering data analysis outcomes favoring clients’ reimbursement and market access strategy 78
4.2.2.4 AI-powered clinical development and decentralized trial models 78

4.2.3 CHALLENGES 79
4.2.3.1 Patient retention 79
4.2.3.2 Cybersecurity or intellectual property challenges 79
4.3 UNMET NEEDS AND WHITE SPACES 79
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 80
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 80
5 INDUSTRY TRENDS 81
5.1 MARKET TRENDS 81
5.1.1 INTEGRATION OF HEOR AND RWE INTO CLINICAL TRIAL DESIGN 81
5.1.2 IN SILICO TRIALS 81
5.1.3 SPECIALIZED BIOANALYTICS FOR EMERGING MODALITIES (CGT) 82
5.2 PORTER’S FIVE FORCES ANALYSIS 83
5.2.1 THREAT OF NEW ENTRANTS 84
5.2.2 THREAT OF SUBSTITUTES 84
5.2.3 BARGAINING POWER OF BUYERS 84
5.2.4 BARGAINING POWER OF SUPPLIERS 84
5.2.5 INTENSITY OF COMPETITIVE RIVALRY 84
5.3 MACROECONOMIC OUTLOOK 85
5.3.1 INTRODUCTION 85
5.3.2 GDP TRENDS AND FORECAST 85
5.3.3 TRENDS IN GLOBAL CRO SERVICES MARKET 85
5.4 VALUE CHAIN ANALYSIS 86
5.5 ECOSYSTEM ANALYSIS 87
5.6 PRICING ANALYSIS 89
5.6.1 INDICATIVE PRICING RANGE, BY SERVICE TYPE, 2025 89
5.6.2 INDICATIVE PRICING ANALYSIS, BY PHASE, 2025 90
5.6.3 INDICATIVE PRICING ANALYSIS, BY REGION, 2025 90
5.7 KEY CONFERENCES & EVENTS, 2026–2027 91
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 92
5.9 INVESTMENT AND FUNDING SCENARIO 92
5.10 IMPACT OF 2025 US TARIFFS—CRO SERVICES MARKET 93
5.10.1 INTRODUCTION 93
5.10.2 KEY TARIFF RATES 93
5.10.3 PRICE IMPACT ANALYSIS 93
5.10.4 IMPACT ON COUNTRIES/REGIONS 94
5.10.4.1 North America 94
5.10.4.1.1 US 94
5.10.4.2 Europe 94
5.10.4.3 Asia Pacific 95
5.10.5 IMPACT ON END-USE INDUSTRIES 95
5.10.5.1 Pharmaceutical & biotech companies 95
5.10.5.2 Medical device companies 96
5.10.5.3 Academic institutes 96
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, INNOVATIONS, AND FUTURE APPLICATIONS 97
6.1 KEY TECHNOLOGIES 97
6.1.1 AI-INTEGRATED CLINICAL TRIAL MANAGEMENT SYSTEM (CTMS) & ELECTRONIC TRIAL MASTER FILE (ETMF) PLATFORMS 97
6.1.2 RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT (RTSM) 97
6.1.3 ELECTRONIC DATA CAPTURE (EDC) SYSTEM 98
6.2 COMPLEMENTARY TECHNOLOGIES 98
6.2.1 DIGITAL BIOMARKERS, WEARABLES & ELECTRONIC PATIENT-REPORTED OUTCOME (EPRO) TOOLS 98
6.2.2 MODEL-INFORMED DRUG DEVELOPMENT (MIDD) 99
6.2.3 DATA MANAGEMENT AND INFORMATICS TECHNOLOGIES 99
6.2.4 REAL-WORLD EVIDENCE (RWE) & REAL-WORLD DATA (RWD) PLATFORMS 100
6.3 ADJACENT TECHNOLOGIES 100
6.3.1 CLINICAL TRIAL SIMULATION TOOLS 100
6.4 TECHNOLOGY/SERVICE ROADMAP 100
6.5 FUTURE APPLICATIONS 101
6.6 IMPACT OF AI/GEN AI ON CRO SERVICES MARKET 101
6.6.1 INTRODUCTION 101
6.6.2 MARKET POTENTIAL ACROSS DRUG DEVELOPMENT STAGES 101
6.6.3 AI USE CASES 102
6.6.4 FUTURE OF GENERATIVE AI IN DRUG DEVELOPMENT ECOSYSTEM 103
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 104
7.1 REGIONAL REGULATIONS AND COMPLIANCE 104
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 104
7.1.2 INDUSTRY STANDARDS 106
7.1.2.1 North America 106
7.1.2.2 Europe 108
7.1.2.3 Asia Pacific 108
7.1.2.4 Rest of the World 109
7.1.3 CERTIFICATIONS, LABELING, & ECO-STANDARDS 110
7.1.4 REGULATORY ANALYSIS 111
7.1.5 REGULATORY SCENARIO FOR DRUG APPROVALS AND CGMP PROCEDURES 111
7.2 SUSTAINABILITY INITIATIVES 114

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 115
8.1 DECISION-MAKING PROCESS 115
8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA 115
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 115
8.2.2 BUYING CRITERIA 116
8.3 CUSTOMER LANDSCAPE 117
8.3.1 BUDGET ALLOCATION TREND 117
8.3.2 ADOPTION BARRIERS & INTERNAL CHALLENGES 118
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 118
8.5 MARKET PROFITABILITY 119
9 CRO SERVICES MARKET, BY TYPE 120
9.1 INTRODUCTION 121
9.2 CLINICAL RESEARCH SERVICES 121
9.2.1 PHASE III 126
9.2.1.1 Large-scale testing ability to assess efficacy and safety of drugs to aid growth 126
9.2.2 PHASE II 129
9.2.2.1 Growing number of pipeline products in Phase II studies to drive market 129
9.2.3 PHASE I 133
9.2.3.1 Robust pipeline of pharmaceutical and biopharmaceutical products to support growth 133
9.2.4 PHASE IV 136
9.2.4.1 Stringent global regulations for drug safety monitoring to spur growth 136
9.3 EARLY-PHASE DEVELOPMENT SERVICES 138
9.3.1 CHEMISTRY, MANUFACTURING, AND CONTROLS SERVICES 141
9.3.1.1 Growing need to meet regulatory norms for drugs to fuel market 141
9.3.2 PRECLINICAL SERVICES 144
9.3.2.1 Pharmacokinetics/Pharmacodynamics 147
9.3.2.1.1 Rise in outsourcing services by pharmaceutical and biopharmaceutical companies to promote growth 147
9.3.2.2 Toxicology testing 150
9.3.2.2.1 Need to prevent late-stage failures to contribute to growth 150
9.3.2.3 Other preclinical services 153
9.3.3 DISCOVERY STUDIES 156
9.3.3.1 Increasing reliance on CRO services for target identification and validation to expedite growth 156
9.4 LABORATORY SERVICES 159
9.4.1 ANALYTICAL TESTING 162
9.4.1.1 Physical characterization 165
9.4.1.1.1 Ability to minimize product failure in late-phase development to favor growth 165
9.4.1.2 Raw material testing 168
9.4.1.2.1 Need to maintain quality of finished product to facilitate growth 168
9.4.1.3 Batch-release testing 172
9.4.1.3.1 Need to maintain batch-to-batch consistency of pharmaceutical dosage forms to advance growth 172
9.4.1.4 Stability testing 174
9.4.1.4.1 Ability to establish drug compatibility and formulation development to aid growth 174
9.4.1.5 Other analytical testing services 178
9.4.2 BIOANALYTICAL TESTING 180
9.4.2.1 Increasing outsourcing of R&D activities to accelerate growth 180
9.5 CONSULTING SERVICES 184
9.5.1 GROWING ADOPTION OF CONSULTING SERVICES FOR FASTER REGULATORY APPROVALS TO BOOST MARKET 184
9.6 DATA MANAGEMENT SERVICES 187
9.6.1 NEED TO TRACK PROGRESS OF EARLY DRUG DEVELOPMENT TO AUGMENT GROWTH 187
10 CRO SERVICES MARKET, BY DELIVERY MODEL 191
10.1 INTRODUCTION 192
10.2 FULL-SERVICE OUTSOURCING (FSO) MODEL 192
10.2.1 RISE IN NUMBER OF EMERGING BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET 192
10.3 FUNCTIONAL SERVICE PROVIDER (FSP) MODEL 195
10.3.1 GROWING ADOPTION OF FSP SERVICES BY LARGE PHARMACEUTICAL COMPANIES TO FUEL MARKET GROWTH 195
10.4 HYBRID MODEL 198
10.4.1 HIGH FLEXIBILITY OFFERED BY HYBRID MODEL TO SUPPORT MARKET GROWTH 198
11 CRO SERVICES MARKET, BY MODALITY 201
11.1 INTRODUCTION 202
11.2 SMALL MOLECULES 202
11.2.1 ONGOING SURGE IN PHARMACEUTICAL R&D INVESTMENTS TO SUPPORT GROWTH 202
11.3 BIOLOGICS 205
11.3.1 MONOCLONAL ANTIBODIES 209
11.3.1.1 Surging demand for targeted therapies across oncology, autoimmune disorders, and infectious diseases to drive market 209
11.3.2 CELL & GENE THERAPY 212
11.3.2.1 Robust pipeline and R&D initiatives to drive market 212
11.3.3 OTHER BIOLOGICS 216

11.4 MEDICAL DEVICES 219
11.4.1 RAPID INNOVATIONS IN DIAGNOSTICS, IMPLANTABLES, AND DIGITAL HEALTH TECHNOLOGIES TO FOSTER GROWTH 219
11.5 BIOSIMILARS 221
11.5.1 MONOCLONAL ANTIBODY BIOSIMILARS 225
11.5.1.1 Rising demand for affordable therapeutic options to support growth 225
11.5.2 INSULIN 228
11.5.2.1 Increasing patent expirations to contribute to growth 228
11.5.3 COLONY-STIMULATING FACTORS 231
11.5.3.1 Increasing use of colony-stimulating factor during post-chemotherapy to aid growth 231
11.5.4 ERYTHROPOIETIN 234
11.5.4.1 Essential role of erythropoietin in treating anemia to stimulate growth 234
11.5.5 OTHER BIOSIMILARS 237
12 CRO SERVICES MARKET, BY THERAPEUTIC AREA 240
12.1 INTRODUCTION 241
12.2 ONCOLOGY 242
12.2.1 GROWING INCIDENCE OF CANCER TO DRIVE MARKET 242
12.2.2 BREAST CANCER 246
12.2.2.1 Increasing cases and high spending on treating breast cancer to support growth 246
12.2.3 LUNG CANCER 249
12.2.3.1 Increasing focus on developing drugs against lung cancer to foster growth 249
12.2.4 COLORECTAL CANCER 252
12.2.4.1 Increasing drug discovery and development efforts against colorectal cancer to aid growth 252
12.2.5 PROSTATE CANCER 254
12.2.5.1 Growing clinical pipeline to propel market 254
12.2.6 OTHER CANCERS 257
12.3 INFECTIOUS DISEASES 260
12.3.1 INCREASING INCIDENCE OF CHRONIC INFECTIONS TO SUPPORT GROWTH 260
12.4 CARDIOVASCULAR SYSTEM DISORDERS 263
12.4.1 HIGH MORTALITY RATES OF CARDIOVASCULAR DISEASES TO FUEL MARKET 263
12.5 NEUROLOGY 266
12.5.1 GROWING INVESTMENTS IN NEUROLOGICAL DISORDER RESEARCH TO DRIVE MARKET 266
12.6 VACCINES 269
12.6.1 INCREASING FOCUS ON VACCINE DEVELOPMENT TO SPUR GROWTH 269
12.7 METABOLIC DISORDERS/ENDOCRINOLOGY 272
12.7.1 INCREASING GLOBAL DIABETES AND OBESITY POPULATION TO PROMOTE GROWTH 272
12.8 IMMUNOLOGICAL DISORDERS 276
12.8.1 GROWING CLINICAL RESEARCH FOR IMMUNOLOGICAL DISORDERS TO BOOST MARKET 276
12.9 PSYCHIATRY 279
12.9.1 RISING CASES OF PSYCHIATRIC DISORDERS AND DEPRESSION TO SUSTAIN GROWTH 279
12.10 RESPIRATORY DISORDERS 282
12.10.1 RISING INCIDENCE OF CHRONIC RESPIRATORY DISEASE TO FOSTER GROWTH 282
12.11 DERMATOLOGY 285
12.11.1 GROWING FOCUS ON DRUG DEVELOPMENT AGAINST VARIOUS SKIN CONDITIONS TO DRIVE MARKET 285
12.12 OPHTHALMOLOGY 288
12.12.1 GROWTH IN NUMBER OF OPHTHALMOLOGY PIPELINE DRUGS TO SUPPORT SEGMENT GROWTH 288
12.13 GASTROINTESTINAL DISEASES 290
12.13.1 RAPID LIFESTYLE AND DIETARY CHANGES TO AMPLIFY GROWTH 290
12.14 GENITOURINARY & WOMEN’S HEALTH 294
12.14.1 RISING AWARENESS ABOUT EARLY DISEASE DIAGNOSIS AND TREATMENT TO BOLSTER MARKET 294
12.15 HEMATOLOGY 296
12.15.1 INCREASING DRUG APPROVALS FOR DRUGS AGAINST NON-MALIGNANT HEMATOLOGICAL CONDITIONS TO SUPPORT GROWTH 296
12.16 OTHER THERAPEUTIC AREAS 299
13 CRO SERVICES MARKET, BY END USER 303
13.1 INTRODUCTION 304
13.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 304
13.2.1 INCREASING OUTSOURCING AND PARTNERSHIPS TO ACCELERATE GROWTH 304
13.2.2 LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 308
13.2.2.1 Demand for therapeutic expertise and global reach to aid outsourcing to CROs 308
13.2.3 SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 311
13.2.3.1 Demand is driven by need to control fixed costs, access global development expertise, and accelerate timelines 311
13.3 MEDICAL DEVICE COMPANIES 314
13.3.1 INCREASING GROWTH INITIATIVES BY MEDTECH CROS TO DRIVE MARKET 314
13.4 ACADEMIC INSTITUTES 318
13.4.1 CONSISTENT COLLABORATIONS BETWEEN CROS AND ACADEMIA TO INTENSIFY GROWTH 318
14 CRO SERVICES MARKET, BY REGION 322
14.1 INTRODUCTION 323
14.2 NORTH AMERICA 323
14.2.1 US 330
14.2.1.1 Increasing incidence of oncology indications to accelerate growth 330
14.2.2 CANADA 337
14.2.2.1 Favorable government initiatives and high investments to support growth 337
14.3 EUROPE 343
14.3.1 GERMANY 349
14.3.1.1 Presence of strong pharmaceutical and biotechnology R&D infrastructure to spur growth 349
14.3.2 UK 355
14.3.2.1 Rising pharmaceutical R&D expenditure to expedite growth 355
14.3.3 FRANCE 360
14.3.3.1 Increasing technological advancements and faster drug discovery and development initiatives to aid growth 360
14.3.4 ITALY 366
14.3.4.1 Short timeline for drug approvals to encourage growth 366
14.3.5 SPAIN 372
14.3.5.1 Growing investment in pharmaceutical industry to boost market 372
14.3.6 REST OF EUROPE 377
14.4 ASIA PACIFIC 383
14.4.1 CHINA 389
14.4.1.1 Continued efforts on improving the level of drug safety and supply to spur growth 389
14.4.2 INDIA 395
14.4.2.1 Large pool of patients and presence of highly skilled medical professionals to augment growth 395
14.4.3 JAPAN 401
14.4.3.1 Growing drug development activity to propel market 401
14.4.4 AUSTRALIA 407
14.4.4.1 Growing focus on funding opportunities to propel market 407
14.4.5 SOUTH KOREA 413
14.4.5.1 Emerging clinical research hub to sustain growth 413
14.4.6 REST OF ASIA PACIFIC 419
14.5 LATIN AMERICA 425
14.5.1 BRAZIL 431
14.5.1.1 Growing focus on enhancing pharmaceutical research and production to fuel market 431
14.5.2 MEXICO 436
14.5.2.1 Increasing investments in pharma R&D to promote growth 436
14.5.3 REST OF LATIN AMERICA 442
14.6 MIDDLE EAST 447
14.6.1 GCC COUNTRIES 452
14.6.1.1 Kingdom of Saudi Arabia (KSA) 458
14.6.1.1.1 Expanding clinical trials ecosystem to contribute to growth 458
14.6.1.2 United Arab Emirates (UAE) 464
14.6.1.2.1 Growing clinical trials activity to drive market 464
14.6.1.3 Rest of GCC Countries 470
14.6.2 REST OF MIDDLE EAST 475
14.7 AFRICA 481
14.7.1 BOOMING PHARMACEUTICAL INDUSTRY TO FACILITATE GROWTH 481
15 COMPETITIVE LANDSCAPE 487
15.1 INTRODUCTION 487
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 487
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CRO SERVICES MARKET, JANUARY 2023-MARCH 2026 487
15.3 REVENUE ANALYSIS, 2021–2025 489
15.4 MARKET SHARE ANALYSIS, 2025 489
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 492
15.5.1 STARS 492
15.5.2 EMERGING LEADERS 492
15.5.3 PERVASIVE PLAYERS 492
15.5.4 PARTICIPANTS 492
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 494
15.5.5.1 Company footprint 494
15.5.5.2 Region footprint 495
15.5.5.3 Type footprint 496
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 497
15.6.1 PROGRESSIVE COMPANIES 497
15.6.2 RESPONSIVE COMPANIES 497
15.6.3 DYNAMIC COMPANIES 497
15.6.4 STARTING BLOCKS 497
15.6.5 COMPETITIVE BENCHMARKING 499
15.6.5.1 Detailed list of key startups/SMEs 499
15.6.5.2 Competitive benchmarking of startups/SMEs 500
15.7 COMPANY VALUATION & FINANCIAL METRICS 501
15.7.1 FINANCIAL METRICS 501
15.7.2 COMPANY VALUATION 501
15.8 SERVICE COMPARISON 502
15.9 COMPETITIVE SCENARIO 503
15.9.1 SERVICE LAUNCHES & APPROVALS 503
15.9.2 DEALS 504
15.9.3 EXPANSIONS 505

16 COMPANY PROFILES 506
16.1 KEY PLAYERS 506
16.1.1 IQVIA INC. 506
16.1.1.1 Business overview 506
16.1.1.2 Services/Solutions offered 507
16.1.1.3 Recent developments 509
16.1.1.3.1 Product & service launches 509
16.1.1.3.2 Deals 510
16.1.1.4 MnM view 511
16.1.1.4.1 Key strengths/Right to win 511
16.1.1.4.2 Strategic choices made 512
16.1.1.4.3 Weaknesses and competitive threats 512
16.1.2 ICON PLC 513
16.1.2.1 Business overview 513
16.1.2.2 Services/Solutions offered 514
16.1.2.3 Recent developments 516
16.1.2.3.1 Service launches 516
16.1.2.3.2 Deals 516
16.1.2.3.3 Expansions 517
16.1.2.4 MnM view 517
16.1.2.4.1 Key strengths/Right to win 517
16.1.2.4.2 Strategic choices made 517
16.1.2.4.3 Weaknesses and competitive threats 517
16.1.3 THERMO FISHER SCIENTIFIC INC. 518
16.1.3.1 Business overview 518
16.1.3.2 Services/Solutions offered 519
16.1.3.3 Recent developments 521
16.1.3.3.1 Service launches 521
16.1.3.3.2 Deals 522
16.1.3.3.3 Expansions 523
16.1.3.4 MnM view 523
16.1.3.4.1 Key strengths/Right to win 523
16.1.3.4.2 Strategic choices made 524
16.1.3.4.3 Weaknesses and competitive threats 524
16.1.4 LABORATORY CORPORATION OF AMERICA HOLDINGS 525
16.1.4.1 Business overview 525
16.1.4.2 Services/Solutions offered 526
16.1.4.3 Recent developments 528
16.1.4.3.1 Service launches 528
16.1.4.3.2 Deals 528
16.1.4.3.3 Expansions 529
16.1.4.3.4 Other developments 530
16.1.4.4 MnM view 530
16.1.4.4.1 Key strengths/Right to win 530
16.1.4.4.2 Strategic choices made 530
16.1.4.4.3 Weaknesses and competitive threats 530
16.1.5 FORTREA, INC. 531
16.1.5.1 Company overview 531
16.1.5.2 Services/Solutions offered 532
16.1.5.3 Recent developments 534
16.1.5.3.1 Service launches 534
16.1.5.3.2 Deals 535
16.1.5.3.3 Expansions 536
16.1.5.3.4 Other developments 536
16.1.5.4 MnM view 536
16.1.5.4.1 Key strengths/Right to win 536
16.1.5.4.2 Strategic choices made 536
16.1.5.4.3 Weaknesses and competitive threats 536
16.1.6 SYNEOS HEALTH 537
16.1.6.1 Business overview 537
16.1.6.2 Services/Solutions offered 537
16.1.6.3 Recent developments 539
16.1.6.3.1 Service launches 539
16.1.6.3.2 Deals 539
16.1.7 WUXI APPTEC 541
16.1.7.1 Business overview 541
16.1.7.2 Services/Solutions offered 542
16.1.7.3 Recent developments 544
16.1.7.3.1 Expansions 544
16.1.7.3.2 Other developments 545
16.1.8 CHARLES RIVER LABORATORIES 546
16.1.8.1 Business overview 546
16.1.8.2 Services/Solutions offered 547
16.1.8.3 Recent developments 548
16.1.8.3.1 Deals 548
16.1.9 PAREXEL INTERNATIONAL CORPORATION 550
16.1.9.1 Business overview 550
16.1.9.2 Services/Solutions offered 551
16.1.9.3 Recent developments 552
16.1.9.3.1 Deals 552
16.1.9.3.2 Expansions 553
16.1.10 PHARMARON 554
16.1.10.1 Business overview 554
16.1.10.2 Services/Solutions offered 555
16.1.11 MEDPACE 557
16.1.11.1 Business overview 557
16.1.11.2 Services/Solutions offered 558
16.1.12 SGS SA 560
16.1.12.1 Business overview 560
16.1.12.2 Services/Solutions offered 561
16.1.12.3 Recent developments 563
16.1.12.3.1 Deals 563
16.1.13 FRONTAGE LABS 564
16.1.13.1 Business overview 564
16.1.13.2 Services/Solutions offered 565
16.1.13.3 Recent developments 567
16.1.13.3.1 Deals 567
16.1.13.3.2 Other developments 568
16.1.14 EUROFINS SCIENTIFIC 569
16.1.14.1 Business overview 569
16.1.14.2 Services/Solutions offered 570
16.1.15 TIGERMED 572
16.1.15.1 Business overview 572
16.1.15.2 Services offered 573
16.1.15.3 Recent developments 575
16.1.15.3.1 Product/Service approvals 575
16.1.15.3.2 Deals 575
16.1.16 PSI CRO AG 577
16.1.16.1 Business overview 577
16.1.16.2 Services/Solutions offered 577
16.1.16.3 Recent developments 578
16.1.16.3.1 Service launches 578
16.1.16.3.2 Deals 578
16.1.16.3.3 Expansions 579
16.1.17 BIOAGILE 580
16.1.17.1 Business overview 580
16.1.17.2 Services/Solutions offered 580
16.1.18 FIRMA CLINICAL RESEARCH 582
16.1.18.1 Business overview 582
16.1.18.2 Services/Solutions offered 582
16.1.19 ACCULAB LIFE SCIENCES 583
16.1.19.1 Business overview 583
16.1.19.2 Services/Solutions offered 583
16.1.20 NOVOTECH 584
16.1.20.1 Business overview 584
16.1.20.2 Services/Solutions offered 584
16.1.20.3 Recent developments 586
16.1.20.3.1 Deals 586
16.1.21 LINICAL 588
16.1.21.1 Business overview 588
16.1.21.2 Services/Solutions offered 588
16.1.21.3 Recent developments 589
16.1.21.3.1 Expansions 589
16.1.22 ADVANCED CLINICAL 590
16.1.22.1 Business overview 590
16.1.22.2 Services/Solutions offered 590
16.1.22.3 Recent developments 591
16.1.22.3.1 Deals 591
16.2 OTHER PLAYERS 592
16.2.1 ALLUCENT 592
16.2.2 EMVENIO 593
16.2.3 GUIRES INC. (PEPGRA HEALTHCARE PVT. LTD.) 594
16.2.4 WORLDWIDE CLINICAL TRIALS 595
16.2.5 CTI CLINICAL TRIAL & CONSULTING 596
17 RESEARCH METHODOLOGY 598
17.1 RESEARCH APPROACH 598
17.1.1 SECONDARY DATA 599
17.1.1.1 Key sources of secondary data 599
17.1.1.2 Key objectives of secondary research 599
17.1.2 PRIMARY DATA 600
17.1.2.1 Breakdown of primaries 600
17.1.2.2 Key objectives of primary research 600
17.2 MARKET ESTIMATION METHODOLOGY 601
17.2.1 COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH) 601
17.2.2 MNM REPOSITORY ANALYSIS AND PRIMARY RESEARCH 603
17.2.3 SEGMENTAL MARKET ASSESSMENT (TOP-DOWN APPROACH) 604
17.3 GROWTH RATE PROJECTIONS 606
17.4 DATA TRIANGULATION 608
17.5 RESEARCH ASSUMPTIONS 609
17.6 RESEARCH LIMITATIONS 610
17.7 RISK ANALYSIS 610

18 APPENDIX 611
18.1 DISCUSSION GUIDE 611
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 616
18.3 CUSTOMIZATION OPTIONS 618
18.4 RELATED REPORTS 619
18.5 AUTHOR DETAILS 620

LIST OF TABLES

TABLE 1 IMPACT ANALYSIS: CRO SERVICES MARKET 73
TABLE 2 PORTER’S FIVE FORCES ANALYSIS: CRO SERVICES MARKET 83
TABLE 3 CRO SERVICES MARKET: ROLE OF COMPANIES IN ECOSYSTEM 88
TABLE 4 INDICATIVE PRICING RANGE, BY SERVICE TYPE, 2025 (USD) 89
TABLE 5 INDICATIVE PRICING ANALYSIS, BY SERVICE TYPE, 2025 (USD MILLION) 90
TABLE 6 INDICATIVE PRICING ANALYSIS (PER STUDY), BY REGION, 2025 (USD MILLION) 90
TABLE 7 DETAILED LIST OF KEY CONFERENCES & EVENTS, 2026–2027 91
TABLE 8 BEST PRACTICES FOLLOWED BY COMPANIES IN CRO SERVICES MARKET 103
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 104
TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105
TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105
TABLE 12 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 106
TABLE 13 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CRO SERVICES, BY MODALITY 116
TABLE 14 BUYING CRITERIA FOR CRO SERVICES ACROSS END USERS 116
TABLE 15 CRO SERVICES: ADOPTION BARRIERS & INTERNAL FRICTION 118
TABLE 16 CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 121
TABLE 17 CLINICAL RESEARCH SERVICES OFFERED BY MARKET PLAYERS 122
TABLE 18 CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2024–2031 (USD MILLION) 123
TABLE 19 CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 124
TABLE 20 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 124
TABLE 21 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 124
TABLE 22 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 125
TABLE 23 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 125
TABLE 24 MIDDLE EAST: CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 125
TABLE 25 GCC COUNTRIES: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 126
TABLE 26 CLINICAL RESEARCH SERVICES MARKET FOR PHASE III, BY REGION,
2024–2031 (USD MILLION) 127
TABLE 27 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE III,
BY COUNTRY, 2024–2031 (USD MILLION) 127
TABLE 28 EUROPE: CLINICAL RESEARCH SERVICES MARKET FOR PHASE III, BY COUNTRY, 2024–2031 (USD MILLION) 128
TABLE 29 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET FOR PHASE III,
BY COUNTRY, 2024–2031 (USD MILLION) 128
TABLE 30 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE III,
BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 31 MIDDLE EAST: CLINICAL RESEARCH SERVICES MARKET FOR PHASE III,
BY REGION, 2024–2031 (USD MILLION) 129
TABLE 32 GCC COUNTRIES: CLINICAL RESEARCH SERVICES MARKET FOR PHASE III,
BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 33 CLINICAL RESEARCH SERVICES MARKET FOR PHASE II, BY REGION,
2024–2031 (USD MILLION) 130
TABLE 34 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE II,
BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 35 EUROPE: CLINICAL RESEARCH SERVICES MARKET FOR PHASE II, BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 36 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET FOR PHASE II, BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 37 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE II,
BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 38 MIDDLE EAST: CLINICAL RESEARCH SERVICES MARKET FOR PHASE II, BY REGION, 2024–2031 (USD MILLION) 132
TABLE 39 GCC COUNTRIES: CLINICAL RESEARCH SERVICES MARKET FOR PHASE II,
BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 40 CLINICAL RESEARCH SERVICES MARKET FOR PHASE I, BY REGION,
2024–2031 (USD MILLION) 133
TABLE 41 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE I,
BY COUNTRY, 2024–2031 (USD MILLION) 133
TABLE 42 EUROPE: CLINICAL RESEARCH SERVICES MARKET FOR PHASE I, BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 43 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET FOR PHASE I, BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 44 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE I,
BY COUNTRY, 2024–2031 (USD MILLION) 135
TABLE 45 MIDDLE EAST: CLINICAL RESEARCH SERVICES MARKET FOR PHASE I, BY REGION, 2024–2031 (USD MILLION) 135
TABLE 46 GCC COUNTRIES: CLINICAL RESEARCH SERVICES MARKET FOR PHASE I,
BY COUNTRY, 2024–2031 (USD MILLION) 135
TABLE 47 CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY REGION,
2024–2031 (USD MILLION) 136
TABLE 48 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2024–2031 (USD MILLION) 136
TABLE 49 EUROPE: CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 50 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 51 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 52 MIDDLE EAST: CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY REGION, 2024–2031 (USD MILLION) 138
TABLE 53 GCC COUNTRIES: CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 54 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 139
TABLE 55 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 139
TABLE 56 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 139
TABLE 57 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 140
TABLE 58 ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 59 LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 60 MIDDLE EAST: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 141
TABLE 61 GCC COUNTRIES: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 62 CMC SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 142
TABLE 63 NORTH AMERICA: CMC SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 142
TABLE 64 EUROPE: CMC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 143
TABLE 65 ASIA PACIFIC: CMC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 143
TABLE 66 LATIN AMERICA: CMC SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 143
TABLE 67 MIDDLE EAST: CMC SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 144
TABLE 68 GCC COUNTRIES: CMC SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 144
TABLE 69 PRECLINICAL SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 145
TABLE 70 PRECLINICAL SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 145
TABLE 71 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 145
TABLE 72 EUROPE: PRECLINICAL SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 146
TABLE 73 ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 146
TABLE 74 LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 146
TABLE 75 MIDDLE EAST: PRECLINICAL SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 147
TABLE 76 GCC COUNTRIES: PRECLINICAL SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 147
TABLE 77 PK/PD SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 148
TABLE 78 NORTH AMERICA: PK/PD SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148
TABLE 79 EUROPE: PK/PD SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148
TABLE 80 ASIA PACIFIC: PK/PD SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 149
TABLE 81 LATIN AMERICA: PK/PD SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 149
TABLE 82 MIDDLE EAST: PK/PD SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 149
TABLE 83 GCC COUNTRIES: PK/PD SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 150
TABLE 84 TOXICOLOGY TESTING SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 151
TABLE 85 NORTH AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 151
TABLE 86 EUROPE: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 151
TABLE 87 ASIA PACIFIC: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 152
TABLE 88 LATIN AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 152
TABLE 89 MIDDLE EAST: TOXICOLOGY TESTING SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 152
TABLE 90 GCC COUNTRIES: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 153
TABLE 91 OTHER PRECLINICAL SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 153
TABLE 92 NORTH AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 154
TABLE 93 EUROPE: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 154
TABLE 94 ASIA PACIFIC: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 154
TABLE 95 LATIN AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 155
TABLE 96 MIDDLE EAST: OTHER PRECLINICAL SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 155
TABLE 97 GCC COUNTRIES: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 155
TABLE 98 CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY REGION,
2024–2031 (USD MILLION) 156
TABLE 99 NORTH AMERICA: CRO SERVICES MARKET FOR DISCOVERY STUDIES,
BY COUNTRY, 2024–2031 (USD MILLION) 156
TABLE 100 EUROPE: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY COUNTRY,
2024–2031 (USD MILLION) 157
TABLE 101 ASIA PACIFIC: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY COUNTRY, 2024–2031 (USD MILLION) 157
TABLE 102 LATIN AMERICA: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 103 MIDDLE EAST: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY REGION, 2024–2031 (USD MILLION) 158
TABLE 104 GCC COUNTRIES: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 105 LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS 159
TABLE 106 LABORATORY SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 159
TABLE 107 LABORATORY SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 160
TABLE 108 NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 160
TABLE 109 EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 160
TABLE 110 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 161
TABLE 111 LATIN AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 161
TABLE 112 MIDDLE EAST: LABORATORY SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 161
TABLE 113 GCC COUNTRIES: LABORATORY SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 162
TABLE 114 ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 162
TABLE 115 ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 163
TABLE 116 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 163
TABLE 117 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 163
TABLE 118 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 164
TABLE 119 LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 164
TABLE 120 MIDDLE EAST: ANALYTICAL TESTING SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 164
TABLE 121 GCC COUNTRIES: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 165
TABLE 122 CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION, BY REGION,
2024–2031 (USD MILLION) 166
TABLE 123 NORTH AMERICA: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION,
BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 124 EUROPE: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION,
BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 125 ASIA PACIFIC: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION,
BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 126 LATIN AMERICA: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION,
BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 127 MIDDLE EAST: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION,
BY REGION, 2024–2031 (USD MILLION) 167
TABLE 128 GCC COUNTRIES: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION,
BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 129 CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY REGION,
2024–2031 (USD MILLION) 169
TABLE 130 NORTH AMERICA: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 169
TABLE 131 EUROPE: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 132 ASIA PACIFIC: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 133 LATIN AMERICA: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 134 MIDDLE EAST: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY REGION, 2024–2031 (USD MILLION) 171
TABLE 135 GCC COUNTRIES: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 136 CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY REGION,
2024–2031 (USD MILLION) 172
TABLE 137 NORTH AMERICA: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING,
BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 138 EUROPE: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 139 ASIA PACIFIC: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 140 LATIN AMERICA: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 141 MIDDLE EAST: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY REGION, 2024–2031 (USD MILLION) 174
TABLE 142 GCC COUNTRIES: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING,
BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 143 CRO SERVICES MARKET FOR STABILITY TESTING, BY REGION,
2024–2031 (USD MILLION) 175
TABLE 144 NORTH AMERICA: CRO SERVICES MARKET FOR STABILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 145 EUROPE: CRO SERVICES MARKET FOR STABILITY TESTING, BY COUNTRY,
2024–2031 (USD MILLION) 176
TABLE 146 ASIA PACIFIC: CRO SERVICES MARKET FOR STABILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 147 LATIN AMERICA: CRO SERVICES MARKET FOR STABILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 148 MIDDLE EAST: CRO SERVICES MARKET FOR STABILITY TESTING, BY REGION, 2024–2031 (USD MILLION) 177
TABLE 149 GCC COUNTRIES: CRO SERVICES MARKET FOR STABILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 150 OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 178
TABLE 151 NORTH AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 152 EUROPE: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 179
TABLE 153 ASIA PACIFIC: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 154 LATIN AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180
TABLE 155 MIDDLE EAST: OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 180
TABLE 156 GCC COUNTRIES: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180
TABLE 157 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 181
TABLE 158 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 159 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 182
TABLE 160 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 182
TABLE 161 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 162 MIDDLE EAST: BIOANALYTICAL TESTING SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 183
TABLE 163 GCC COUNTRIES: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 164 CONSULTING SERVICES OFFERED BY PROMINENT PLAYERS 184
TABLE 165 CONSULTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 185
TABLE 166 NORTH AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 186
TABLE 167 EUROPE: CONSULTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 186
TABLE 168 ASIA PACIFIC: CONSULTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 186
TABLE 169 LATIN AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 187
TABLE 170 MIDDLE EAST: CONSULTING SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 187
TABLE 171 GCC COUNTRIES: CONSULTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 187
TABLE 172 DATA MANAGEMENT SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 188
TABLE 173 NORTH AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 188
TABLE 174 EUROPE: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 189
TABLE 175 ASIA PACIFIC: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 189
TABLE 176 LATIN AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 190
TABLE 177 MIDDLE EAST: DATA MANAGEMENT SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 190
TABLE 178 GCC COUNTRIES: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 190
TABLE 179 CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 192
TABLE 180 CRO SERVICES MARKET FOR FSO MODEL, BY REGION, 2024–2031 (USD MILLION) 193
TABLE 181 NORTH AMERICA: CRO SERVICES MARKET FOR FSO MODEL, BY COUNTRY,
2024–2031 (USD MILLION) 193
TABLE 182 EUROPE: CRO SERVICES MARKET FOR FSO MODEL, BY COUNTRY,
2024–2031 (USD MILLION) 193
TABLE 183 ASIA PACIFIC: CRO SERVICES MARKET FOR FSO MODEL, BY COUNTRY,
2024–2031 (USD MILLION) 194
TABLE 184 LATIN AMERICA: CRO SERVICES MARKET FOR FSO MODEL, BY COUNTRY,
2024–2031 (USD MILLION) 194
TABLE 185 MIDDLE EAST: CRO SERVICES MARKET FOR FSO MODEL, BY REGION,
2024–2031 (USD MILLION) 194
TABLE 186 GCC COUNTRIES: CRO SERVICES MARKET FOR FSO MODEL, BY COUNTRY,
2024–2031 (USD MILLION) 195
TABLE 187 CRO SERVICES MARKET FOR FSP MODEL, BY REGION, 2024–2031 (USD MILLION) 196
TABLE 188 NORTH AMERICA: CRO SERVICES MARKET FOR FSP MODEL, BY COUNTRY,
2024–2031 (USD MILLION) 196
TABLE 189 EUROPE: CRO SERVICES MARKET FOR FSP MODEL, BY COUNTRY,
2024–2031 (USD MILLION) 196
TABLE 190 ASIA PACIFIC: CRO SERVICES MARKET FOR FSP MODEL, BY COUNTRY,
2024–2031 (USD MILLION) 197
TABLE 191 LATIN AMERICA: CRO SERVICES MARKET FOR FSP MODEL, BY COUNTRY,
2024–2031 (USD MILLION) 197
TABLE 192 MIDDLE EAST: CRO SERVICES MARKET FOR FSP MODEL, BY REGION,
2024–2031 (USD MILLION) 197
TABLE 193 GCC COUNTRIES: CRO SERVICES MARKET FOR FSP MODEL, BY COUNTRY,
2024–2031 (USD MILLION) 198
TABLE 194 CRO SERVICES MARKET FOR HYBRID MODEL, BY REGION,
2024–2031 (USD MILLION) 198
TABLE 195 NORTH AMERICA: CRO SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 199
TABLE 196 EUROPE: CRO SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY,
2024–2031 (USD MILLION) 199
TABLE 197 ASIA PACIFIC: CRO SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY,
2024–2031 (USD MILLION) 199
TABLE 198 LATIN AMERICA: CRO SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 199 MIDDLE EAST: CRO SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY,
2024–2031 (USD MILLION) 200
TABLE 200 GCC COUNTRIES: CRO SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 201 CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 202
TABLE 202 CRO SERVICES MARKET FOR SMALL MOLECULES, BY REGION,
2024–2031 (USD MILLION) 203
TABLE 203 NORTH AMERICA: CRO SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2031 (USD MILLION) 203
TABLE 204 EUROPE: CRO SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY,
2024–2031 (USD MILLION) 204
TABLE 205 ASIA PACIFIC: CRO SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2031 (USD MILLION) 204
TABLE 206 LATIN AMERICA: CRO SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 207 MIDDLE EAST: CRO SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2024–2031 (USD MILLION) 205
TABLE 208 GCC COUNTRIES: CRO SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 209 CRO SERVICES MARKET FOR BIOLOGICS, BY REGION, 2024–2031 (USD MILLION) 206
TABLE 210 NORTH AMERICA: CRO SERVICES MARKET FOR BIOLOGICS, BY COUNTRY,
2024–2031 (USD MILLION) 206
TABLE 211 EUROPE: CRO SERVICES MARKET FOR BIOLOGICS, BY COUNTRY,
2024–2031 (USD MILLION) 207
TABLE 212 ASIA PACIFIC: CRO SERVICES MARKET FOR BIOLOGICS, BY COUNTRY,
2024–2031 (USD MILLION) 207
TABLE 213 LATIN AMERICA: CRO SERVICES MARKET FOR BIOLOGICS, BY COUNTRY,
2024–2031 (USD MILLION) 208
TABLE 214 MIDDLE EAST: CRO SERVICES MARKET FOR BIOLOGICS, BY REGION,
2024–2031 (USD MILLION) 208
TABLE 215 GCC COUNTRIES: CRO SERVICES MARKET FOR BIOLOGICS, BY COUNTRY,
2024–2031 (USD MILLION) 208
TABLE 216 CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 209
TABLE 217 CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION,
2024–2031 (USD MILLION) 210
TABLE 218 NORTH AMERICA: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES,
BY COUNTRY, 2024–2031 (USD MILLION) 210
TABLE 219 EUROPE: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 220 ASIA PACIFIC: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES,
BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 221 LATIN AMERICA: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES,
BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 222 MIDDLE EAST: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES,
BY REGION, 2024–2031 (USD MILLION) 212
TABLE 223 GCC COUNTRIES: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 224 CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY REGION,
2024–2031 (USD MILLION) 213
TABLE 225 NORTH AMERICA: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 226 EUROPE: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 227 ASIA PACIFIC: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 228 LATIN AMERICA: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION) 215
TABLE 229 MIDDLE EAST: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY REGION, 2024–2031 (USD MILLION) 215
TABLE 230 GCC COUNTRIES: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION) 215
TABLE 231 CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY REGION,
2024–2031 (USD MILLION) 216
TABLE 232 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION) 216
TABLE 233 EUROPE: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY COUNTRY,
2024–2031 (USD MILLION) 217
TABLE 234 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION) 217
TABLE 235 LATIN AMERICA: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION) 218
TABLE 236 MIDDLE EAST: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY REGION, 2024–2031 (USD MILLION) 218
TABLE 237 GCC COUNTRIES: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION) 218
TABLE 238 CRO SERVICES MARKET FOR MEDICAL DEVICES, BY REGION,
2024–2031 (USD MILLION) 219
TABLE 239 NORTH AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2024–2031 (USD MILLION) 220
TABLE 240 EUROPE: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY COUNTRY,
2024–2031 (USD MILLION) 220
TABLE 241 ASIA PACIFIC: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2024–2031 (USD MILLION) 220
TABLE 242 LATIN AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 243 MIDDLE EAST: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY REGION, 2024–2031 (USD MILLION) 221
TABLE 244 GCC COUNTRIES: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 245 CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 222
TABLE 246 CRO SERVICES MARKET FOR BIOSIMILARS, BY REGION,
2024–2031 (USD MILLION) 222
TABLE 247 NORTH AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY,
2024–2031 (USD MILLION) 223
TABLE 248 EUROPE: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY,
2024–2031 (USD MILLION) 223
TABLE 249 ASIA PACIFIC: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY,
2024–2031 (USD MILLION) 223
TABLE 250 LATIN AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY,
2024–2031 (USD MILLION) 224
TABLE 251 MIDDLE EAST: CRO SERVICES MARKET FOR BIOSIMILARS, BY REGION,
2024–2031 (USD MILLION) 224
TABLE 252 GCC COUNTRIES: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY,
2024–2031 (USD MILLION) 224
TABLE 253 CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY REGION, 2024–2031 (USD MILLION) 225
TABLE 254 NORTH AMERICA: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 255 EUROPE: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS,
BY COUNTRY, 2024–2031 (USD MILLION) 226
TABLE 256 ASIA PACIFIC: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 226
TABLE 257 LATIN AMERICA: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 227
TABLE 258 MIDDLE EAST: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY REGION, 2024–2031 (USD MILLION) 227
TABLE 259 GCC COUNTRIES: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 227
TABLE 260 CRO SERVICES MARKET FOR INSULIN, BY REGION, 2024–2031 (USD MILLION) 228
TABLE 261 NORTH AMERICA: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY,
2024–2031 (USD MILLION) 228
TABLE 262 EUROPE: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY,
2024–2031 (USD MILLION) 229
TABLE 263 ASIA PACIFIC: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY,
2024–2031 (USD MILLION) 229
TABLE 264 LATIN AMERICA: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY,
2024–2031 (USD MILLION) 230
TABLE 265 MIDDLE EAST: CRO SERVICES MARKET FOR INSULIN, BY REGION,
2024–2031 (USD MILLION) 230
TABLE 266 GCC COUNTRIES: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY,
2024–2031 (USD MILLION) 230
TABLE 267 CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY REGION,
2024–2031 (USD MILLION) 231
TABLE 268 NORTH AMERICA: CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 231
TABLE 269 EUROPE: CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 232
TABLE 270 ASIA PACIFIC: CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS,
BY COUNTRY, 2024–2031 (USD MILLION) 232
TABLE 271 LATIN AMERICA: CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS,
BY COUNTRY, 2024–2031 (USD MILLION) 233
TABLE 272 MIDDLE EAST: CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY REGION, 2024–2031 (USD MILLION) 233
TABLE 273 GCC COUNTRIES: CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 233
TABLE 274 CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY REGION,
2024–2031 (USD MILLION) 234
TABLE 275 NORTH AMERICA: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2024–2031 (USD MILLION) 234
TABLE 276 EUROPE: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY,
2024–2031 (USD MILLION) 235
TABLE 277 ASIA PACIFIC: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2024–2031 (USD MILLION) 235
TABLE 278 LATIN AMERICA: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2024–2031 (USD MILLION) 236
TABLE 279 MIDDLE EAST: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY REGION,
2024–2031 (USD MILLION) 236
TABLE 280 GCC COUNTRIES: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2024–2031 (USD MILLION) 236
TABLE 281 CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY REGION,
2024–2031 (USD MILLION) 237
TABLE 282 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 237
TABLE 283 EUROPE: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY,
2024–2031 (USD MILLION) 238
TABLE 284 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 238
TABLE 285 LATIN AMERICA: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 286 MIDDLE EAST: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY REGION, 2024–2031 (USD MILLION) 239
TABLE 287 GCC COUNTRIES: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 288 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 241
TABLE 289 NUMBER OF NEW CANCER CASES, BY TYPE, 2020 VS. 2040 242
TABLE 290 CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 243
TABLE 291 CRO SERVICES MARKET FOR ONCOLOGY, BY REGION, 2024–2031 (USD MILLION) 244
TABLE 292 NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 244
TABLE 293 EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 244
TABLE 294 ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 245
TABLE 295 LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 245
TABLE 296 MIDDLE EAST: CRO SERVICES MARKET FOR ONCOLOGY, BY REGION,
2024–2031 (USD MILLION) 245
TABLE 297 GCC COUNTRIES: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 246
TABLE 298 CRO SERVICES MARKET FOR BREAST CANCER, BY REGION,
2024–2031 (USD MILLION) 247
TABLE 299 NORTH AMERICA: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 247
TABLE 300 EUROPE: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 247
TABLE 301 ASIA PACIFIC: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 248
TABLE 302 LATIN AMERICA: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 248
TABLE 303 MIDDLE EAST: CRO SERVICES MARKET FOR BREAST CANCER, BY REGION,
2024–2031 (USD MILLION) 248
TABLE 304 GCC COUNTRIES: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 249
TABLE 305 CRO SERVICES MARKET FOR LUNG CANCER, BY REGION,
2024–2031 (USD MILLION) 249
TABLE 306 NORTH AMERICA: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 250
TABLE 307 EUROPE: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 250
TABLE 308 ASIA PACIFIC: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 250
TABLE 309 LATIN AMERICA: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 251
TABLE 310 MIDDLE EAST: CRO SERVICES MARKET FOR LUNG CANCER, BY REGION,
2024–2031 (USD MILLION) 251
TABLE 311 GCC COUNTRIES: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 251
TABLE 312 CRO SERVICES MARKET FOR COLORECTAL CANCER, BY REGION,
2024–2031 (USD MILLION) 252
TABLE 313 NORTH AMERICA: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 253
TABLE 314 EUROPE: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 253
TABLE 315 ASIA PACIFIC: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 253
TABLE 316 LATIN AMERICA: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 254
TABLE 317 MIDDLE EAST: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY REGION, 2024–2031 (USD MILLION) 254
TABLE 318 GCC COUNTRIES: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 254
TABLE 319 CRO SERVICES MARKET FOR PROSTATE CANCER, BY REGION,
2024–2031 (USD MILLION) 255
TABLE 320 NORTH AMERICA: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 256
TABLE 321 EUROPE: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 256
TABLE 322 ASIA PACIFIC: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 256
TABLE 323 LATIN AMERICA: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 257
TABLE 324 MIDDLE EAST: CRO SERVICES MARKET FOR PROSTATE CANCER, BY REGION, 2024–2031 (USD MILLION) 257
TABLE 325 GCC COUNTRIES: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 257
TABLE 326 NUMBER OF DRUGS IN R&D PIPELINE FOR OTHER CANCERS, 2023–2025 258
TABLE 327 CRO SERVICES MARKET FOR OTHER CANCERS, BY REGION,
2024–2031 (USD MILLION) 258
TABLE 328 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION) 258
TABLE 329 EUROPE: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY,
2024–2031 (USD MILLION) 259
TABLE 330 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY,
2024–2031 (USD MILLION) 259
TABLE 331 LATIN AMERICA: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION) 259
TABLE 332 MIDDLE EAST: CRO SERVICES MARKET FOR OTHER CANCERS, BY REGION,
2024–2031 (USD MILLION) 260
TABLE 333 GCC COUNTRIES: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION) 260
TABLE 334 CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION,
2024–2031 (USD MILLION) 261
TABLE 335 NORTH AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 261
TABLE 336 EUROPE: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 262
TABLE 337 ASIA PACIFIC: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 262
TABLE 338 LATIN AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 263
TABLE 339 MIDDLE EAST: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 263
TABLE 340 GCC COUNTRIES: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 263
TABLE 341 CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2024–2031 (USD MILLION) 264
TABLE 342 NORTH AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 265
TABLE 343 EUROPE: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 265
TABLE 344 ASIA PACIFIC: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 265
TABLE 345 LATIN AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 266
TABLE 346 MIDDLE EAST: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2024–2031 (USD MILLION) 266
TABLE 347 GCC COUNTRIES: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 266
TABLE 348 CRO SERVICES MARKET FOR NEUROLOGY, BY REGION,
2024–2031 (USD MILLION) 267
TABLE 349 NORTH AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 268
TABLE 350 EUROPE: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 268
TABLE 351 ASIA PACIFIC: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 268
TABLE 352 LATIN AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 269
TABLE 353 MIDDLE EAST: CRO SERVICES MARKET FOR NEUROLOGY, BY REGION,
2024–2031 (USD MILLION) 269
TABLE 354 GCC COUNTRIES: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 269
TABLE 355 CRO SERVICES MARKET FOR VACCINES, BY REGION, 2024–2031 (USD MILLION) 270
TABLE 356 NORTH AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY,
2024–2031 (USD MILLION) 270
TABLE 357 EUROPE: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY,
2024–2031 (USD MILLION) 271
TABLE 358 ASIA PACIFIC: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY,
2024–2031 (USD MILLION) 271
TABLE 359 LATIN AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY,
2024–2031 (USD MILLION) 271
TABLE 360 MIDDLE EAST: CRO SERVICES MARKET FOR VACCINES, BY REGION,
2024–2031 (USD MILLION) 272
TABLE 361 GCC COUNTRIES: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY,
2024–2031 (USD MILLION) 272
TABLE 362 CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY,
BY REGION, 2024–2031 (USD MILLION) 274
TABLE 363 NORTH AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 274
TABLE 364 EUROPE: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 274
TABLE 365 ASIA PACIFIC: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 275
TABLE 366 LATIN AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 275
TABLE 367 MIDDLE EAST: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2024–2031 (USD MILLION) 275
TABLE 368 GCC COUNTRIES: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 276
TABLE 369 CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION,
2024–2031 (USD MILLION) 277
TABLE 370 NORTH AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 277
TABLE 371 EUROPE: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 277
TABLE 372 ASIA PACIFIC: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 278
TABLE 373 LATIN AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 278
TABLE 374 MIDDLE EAST: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS,
BY REGION, 2024–2031 (USD MILLION) 278
TABLE 375 GCC COUNTRIES: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 279
TABLE 376 CRO SERVICES MARKET FOR PSYCHIATRY, BY REGION,
2024–2031 (USD MILLION) 280
TABLE 377 NORTH AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY,
2024–2031 (USD MILLION) 280
TABLE 378 EUROPE: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY,
2024–2031 (USD MILLION) 280
TABLE 379 ASIA PACIFIC: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY,
2024–2031 (USD MILLION) 281
TABLE 380 LATIN AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY,
2024–2031 (USD MILLION) 281
TABLE 381 MIDDLE EAST: CRO SERVICES MARKET FOR PSYCHIATRY, BY REGION,
2024–2031 (USD MILLION) 281
TABLE 382 GCC COUNTRIES: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY,
2024–2031 (USD MILLION) 282
TABLE 383 CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION,
2024–2031 (USD MILLION) 283
TABLE 384 NORTH AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 283
TABLE 385 EUROPE: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 283
TABLE 386 ASIA PACIFIC: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 284
TABLE 387 LATIN AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 284
TABLE 388 MIDDLE EAST: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS,
BY REGION, 2024–2031 (USD MILLION) 284
TABLE 389 GCC COUNTRIES: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 285
TABLE 390 CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION,
2024–2031 (USD MILLION) 286
TABLE 391 NORTH AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 286
TABLE 392 EUROPE: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 286
TABLE 393 ASIA PACIFIC: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 287
TABLE 394 LATIN AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 287
TABLE 395 MIDDLE EAST: CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION,
2024–2031 (USD MILLION) 287
TABLE 396 GCC COUNTRIES: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 288
TABLE 397 CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION,
2024–2031 (USD MILLION) 288
TABLE 398 NORTH AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 289
TABLE 399 EUROPE: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 289
TABLE 400 ASIA PACIFIC: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 289
TABLE 401 LATIN AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 290
TABLE 402 MIDDLE EAST: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION,
2024–2031 (USD MILLION) 290
TABLE 403 GCC COUNTRIES: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 290
TABLE 404 CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION,
2024–2031 (USD MILLION) 291
TABLE 405 NORTH AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 291
TABLE 406 EUROPE: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 292
TABLE 407 ASIA PACIFIC: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 292
TABLE 408 LATIN AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 293
TABLE 409 MIDDLE EAST: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2024–2031 (USD MILLION) 293
TABLE 410 GCC COUNTRIES: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 293
TABLE 411 CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY REGION, 2024–2031 (USD MILLION) 294
TABLE 412 NORTH AMERICA: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2024–2031 (USD MILLION) 295
TABLE 413 EUROPE: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2024–2031 (USD MILLION) 295
TABLE 414 ASIA PACIFIC: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2024–2031 (USD MILLION) 295
TABLE 415 LATIN AMERICA: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2024–2031 (USD MILLION) 296
TABLE 416 MIDDLE EAST: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY REGION, 2024–2031 (USD MILLION) 296
TABLE 417 GCC COUNTRIES: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2024–2031 (USD MILLION) 296
TABLE 418 CRO SERVICES MARKET FOR HEMATOLOGY, BY REGION,
2024–2031 (USD MILLION) 297
TABLE 419 NORTH AMERICA: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 297
TABLE 420 EUROPE: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 298
TABLE 421 ASIA PACIFIC: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 298
TABLE 422 LATIN AMERICA: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 298
TABLE 423 MIDDLE EAST: CRO SERVICES MARKET FOR HEMATOLOGY, BY REGION,
2024–2031 (USD MILLION) 299
TABLE 424 GCC COUNTRIES: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 299
TABLE 425 CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION,
2024–2031 (USD MILLION) 300
TABLE 426 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS,
BY COUNTRY, 2024–2031 (USD MILLION) 300
TABLE 427 EUROPE: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 300
TABLE 428 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS,
BY COUNTRY, 2024–2031 (USD MILLION) 301
TABLE 429 LATIN AMERICA: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS,
BY COUNTRY, 2024–2031 (USD MILLION) 301
TABLE 430 MIDDLE EAST: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS,
BY REGION, 2024–2031 (USD MILLION) 301
TABLE 431 GCC COUNTRIES: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS,
BY COUNTRY, 2024–2031 (USD MILLION) 302
TABLE 432 CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 304
TABLE 433 CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 306
TABLE 434 CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION) 306
TABLE 435 NORTH AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 307
TABLE 436 EUROPE: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 307
TABLE 437 ASIA PACIFIC: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 307
TABLE 438 LATIN AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 308
TABLE 439 MIDDLE EAST: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION) 308
TABLE 440 GCC COUNTRIES: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 308
TABLE 441 CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION) 309
TABLE 442 NORTH AMERICA: CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 309
TABLE 443 EUROPE: CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 310
TABLE 444 ASIA PACIFIC: CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 310
TABLE 445 LATIN AMERICA: CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 311
TABLE 446 MIDDLE EAST: CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION) 311
TABLE 447 GCC COUNTRIES: CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 311
TABLE 448 CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION) 312
TABLE 449 NORTH AMERICA: CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 312
TABLE 450 EUROPE: CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 313
TABLE 451 ASIA PACIFIC: CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 313
TABLE 452 LATIN AMERICA: CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 314
TABLE 453 MIDDLE EAST: CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION) 314
TABLE 454 GCC COUNTRIES: CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 314
TABLE 455 CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION,
2024–2031 (USD MILLION) 316
TABLE 456 NORTH AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES,
BY COUNTRY, 2024–2031 (USD MILLION) 316
TABLE 457 EUROPE: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES,
BY COUNTRY, 2024–2031 (USD MILLION) 316
TABLE 458 ASIA PACIFIC: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES,
BY COUNTRY, 2024–2031 (USD MILLION) 317
TABLE 459 LATIN AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES,
BY COUNTRY, 2024–2031 (USD MILLION) 317
TABLE 460 MIDDLE EAST: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES,
BY REGION, 2024–2031 (USD MILLION) 317
TABLE 461 GCC COUNTRIES: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES,
BY COUNTRY, 2024–2031 (USD MILLION) 318
TABLE 462 CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION,
2024–2031 (USD MILLION) 319
TABLE 463 NORTH AMERICA: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES,
BY COUNTRY, 2024–2031 (USD MILLION) 319
TABLE 464 EUROPE: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 320
TABLE 465 ASIA PACIFIC: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 320
TABLE 466 LATIN AMERICA: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES,
BY COUNTRY, 2024–2031 (USD MILLION) 321
TABLE 467 MIDDLE EAST: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 321
TABLE 468 GCC COUNTRIES: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES,
BY COUNTRY, 2024–2031 (USD MILLION) 321
TABLE 469 CRO SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 323
TABLE 470 NORTH AMERICA: CRO SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 324
TABLE 471 NORTH AMERICA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 325
TABLE 472 NORTH AMERICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 325
TABLE 473 NORTH AMERICA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 326
TABLE 474 NORTH AMERICA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 326
TABLE 475 NORTH AMERICA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 326
TABLE 476 NORTH AMERICA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 327
TABLE 477 NORTH AMERICA: CRO SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 327
TABLE 478 NORTH AMERICA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 327
TABLE 479 NORTH AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,
2024–2031 (USD MILLION) 328
TABLE 480 NORTH AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 328
TABLE 481 NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 329
TABLE 482 NORTH AMERICA: CRO SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 329
TABLE 483 NORTH AMERICA: CRO SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 330
TABLE 484 NORTH AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 330
TABLE 485 US: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 332
TABLE 486 US: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 332
TABLE 487 US: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES,
BY TYPE, 2024–2031 (USD MILLION) 332
TABLE 488 US: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,
2024–2031 (USD MILLION) 333
TABLE 489 US: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,
2024–2031 (USD MILLION) 333
TABLE 490 US: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,
2024–2031 (USD MILLION) 333
TABLE 491 US: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 334
TABLE 492 US: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 334
TABLE 493 US: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,
2024–2031 (USD MILLION) 334
TABLE 494 US: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 335
TABLE 495 US: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 335
TABLE 496 US: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 336
TABLE 497 US: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 336
TABLE 498 US: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 336
TABLE 499 CANADA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 337
TABLE 500 CANADA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 338
TABLE 501 CANADA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES,
BY TYPE, 2024–2031 (USD MILLION) 338
TABLE 502 CANADA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,
2024–2031 (USD MILLION) 338
TABLE 503 CANADA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,
2024–2031 (USD MILLION) 339
TABLE 504 CANADA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,
2024–2031 (USD MILLION) 339
TABLE 505 CANADA: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 339
TABLE 506 CANADA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 340
TABLE 507 CANADA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,
2024–2031 (USD MILLION) 340
TABLE 508 CANADA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 341
TABLE 509 CANADA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 341
TABLE 510 CANADA: CRO SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 342
TABLE 511 CANADA: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 342
TABLE 512 CANADA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 342
TABLE 513 EUROPE: CRO SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 343
TABLE 514 EUROPE: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 344
TABLE 515 EUROPE: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 344
TABLE 516 EUROPE: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 344
TABLE 517 EUROPE: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,
2024–2031 (USD MILLION) 345
TABLE 518 EUROPE: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,
2024–2031 (USD MILLION) 345
TABLE 519 EUROPE: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,
2024–2031 (USD MILLION) 345
TABLE 520 EUROPE: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 346
TABLE 521 EUROPE: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 346
TABLE 522 EUROPE: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,
2024–2031 (USD MILLION) 346
TABLE 523 EUROPE: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 347
TABLE 524 EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 347
TABLE 525 EUROPE: CRO SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 348
TABLE 526 EUROPE: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 348
TABLE 527 EUROPE: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 348
TABLE 528 GERMANY: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 349
TABLE 529 GERMANY: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 350
TABLE 530 GERMANY: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 350
TABLE 531 GERMANY: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,
2024–2031 (USD MILLION) 350
TABLE 532 GERMANY: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,
2024–2031 (USD MILLION) 351
TABLE 533 GERMANY: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,
2024–2031 (USD MILLION) 351
TABLE 534 GERMANY: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 351
TABLE 535 GERMANY: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 352
TABLE 536 GERMANY: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,
2024–2031 (USD MILLION) 352
TABLE 537 GERMANY: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 353
TABLE 538 GERMANY: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 353
TABLE 539 GERMANY: CRO SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 354
TABLE 540 GERMANY: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 354
TABLE 541 GERMANY: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 354
TABLE 542 UK: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 355
TABLE 543 UK: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 356
TABLE 544 UK: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES,
BY TYPE, 2024–2031 (USD MILLION) 356
TABLE 545 UK: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,
2024–2031 (USD MILLION) 356
TABLE 546 UK: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,
2024–2031 (USD MILLION) 357
TABLE 547 UK: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,
2024–2031 (USD MILLION) 357
TABLE 548 UK: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 357
TABLE 549 UK: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 358
TABLE 550 UK: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,
2024–2031 (USD MILLION) 358
TABLE 551 UK: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 359
TABLE 552 UK: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 359
TABLE 553 UK: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 360
TABLE 554 UK: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 360
TABLE 555 UK: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 360
TABLE 556 FRANCE: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 361
TABLE 557 FRANCE: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 361
TABLE 558 FRANCE: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 362
TABLE 559 FRANCE: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,
2024–2031 (USD MILLION) 362
TABLE 560 FRANCE: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,
2024–2031 (USD MILLION) 362
TABLE 561 FRANCE: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,
2024–2031 (USD MILLION) 363
TABLE 562 FRANCE: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 363
TABLE 563 FRANCE: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 363
TABLE 564 FRANCE: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,
2024–2031 (USD MILLION) 364
TABLE 565 FRANCE: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 364
TABLE 566 FRANCE: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 365
TABLE 567 FRANCE: CRO SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 365
TABLE 568 FRANCE: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 365
TABLE 569 FRANCE: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 366
TABLE 570 ITALY: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 366
TABLE 571 ITALY: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 367
TABLE 572 ITALY: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 367
TABLE 573 ITALY: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,
2024–2031 (USD MILLION) 367
TABLE 574 ITALY: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,
2024–2031 (USD MILLION) 368
TABLE 575 ITALY: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,
2024–2031 (USD MILLION) 368
TABLE 576 ITALY: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 368
TABLE 577 ITALY: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 369
TABLE 578 ITALY: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,
2024–2031 (USD MILLION) 369
TABLE 579 ITALY: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 370
TABLE 580 ITALY: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 370
TABLE 581 ITALY: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 371
TABLE 582 ITALY: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 371
TABLE 583 ITALY: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 371
TABLE 584 SPAIN: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 372
TABLE 585 SPAIN: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 372
TABLE 586 SPAIN: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES,
BY TYPE, 2024–2031 (USD MILLION) 373
TABLE 587 SPAIN: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,
2024–2031 (USD MILLION) 373
TABLE 588 SPAIN: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,
2024–2031 (USD MILLION) 373
TABLE 589 SPAIN: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,
2024–2031 (USD MILLION) 374
TABLE 590 SPAIN: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 374
TABLE 591 SPAIN: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 374
TABLE 592 SPAIN: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,
2024–2031 (USD MILLION) 375
TABLE 593 SPAIN: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 375
TABLE 594 SPAIN: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 376
TABLE 595 SPAIN: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 376
TABLE 596 SPAIN: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 376
TABLE 597 SPAIN: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 377
TABLE 598 REST OF EUROPE: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 378
TABLE 599 REST OF EUROPE: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 378
TABLE 600 REST OF EUROPE: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 378
TABLE 601 REST OF EUROPE: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 379
TABLE 602 REST OF EUROPE: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 379
TABLE 603 REST OF EUROPE: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 379
TABLE 604 REST OF EUROPE: CRO SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 380
TABLE 605 REST OF EUROPE: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 380
TABLE 606 REST OF EUROPE: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,
2024–2031 (USD MILLION) 380
TABLE 607 REST OF EUROPE: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 381
TABLE 608 REST OF EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 381
TABLE 609 REST OF EUROPE: CRO SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 382
TABLE 610 REST OF EUROPE: CRO SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 382
TABLE 611 REST OF EUROPE: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 382
TABLE 612 ASIA PACIFIC: CRO SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 384
TABLE 613 ASIA PACIFIC: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 384
TABLE 614 ASIA PACIFIC: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 384
TABLE 615 ASIA PACIFIC: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 385
TABLE 616 ASIA PACIFIC: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 385
TABLE 617 ASIA PACIFIC: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 385
TABLE 618 ASIA PACIFIC: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,
2024–2031 (USD MILLION) 386
TABLE 619 ASIA PACIFIC: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 386
TABLE 620 ASIA PACIFIC: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 386
TABLE 621 ASIA PACIFIC: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,
2024–2031 (USD MILLION) 387
TABLE 622 ASIA PACIFIC: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 387
TABLE 623 ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 388
TABLE 624 ASIA PACIFIC: CRO SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 388
TABLE 625 ASIA PACIFIC: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 388
TABLE 626 ASIA PACIFIC: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 389
TABLE 627 CHINA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 390
TABLE 628 CHINA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 390
TABLE 629 CHINA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES,
BY TYPE, 2024–2031 (USD MILLION) 391
TABLE 630 CHINA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,
2024–2031 (USD MILLION) 391
TABLE 631 CHINA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,
2024–2031 (USD MILLION) 391
TABLE 632 CHINA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,
2024–2031 (USD MILLION) 392
TABLE 633 CHINA: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 392
TABLE 634 CHINA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 392
TABLE 635 CHINA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,
2024–2031 (USD MILLION) 393
TABLE 636 CHINA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 393
TABLE 637 CHINA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 394
TABLE 638 CHINA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 394
TABLE 639 CHINA: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 394
TABLE 640 CHINA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 395
TABLE 641 INDIA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 396
TABLE 642 INDIA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 396
TABLE 643 INDIA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 396
TABLE 644 INDIA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,
2024–2031 (USD MILLION) 397
TABLE 645 INDIA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,
2024–2031 (USD MILLION) 397
TABLE 646 INDIA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,
2024–2031 (USD MILLION) 397
TABLE 647 INDIA: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 398
TABLE 648 INDIA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 398
TABLE 649 INDIA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,
2024–2031 (USD MILLION) 398
TABLE 650 INDIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 399
TABLE 651 INDIA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 399
TABLE 652 INDIA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 400
TABLE 653 INDIA: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 400
TABLE 654 INDIA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 400
TABLE 655 JAPAN: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 401
TABLE 656 JAPAN: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 402
TABLE 657 JAPAN: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES,
BY TYPE, 2024–2031 (USD MILLION) 402
TABLE 658 JAPAN: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,
2024–2031 (USD MILLION) 402
TABLE 659 JAPAN: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,
2024–2031 (USD MILLION) 403
TABLE 660 JAPAN: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,
2024–2031 (USD MILLION) 403
TABLE 661 JAPAN: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 403
TABLE 662 JAPAN: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 404
TABLE 663 JAPAN: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,
2024–2031 (USD MILLION) 404
TABLE 664 JAPAN: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 405
TABLE 665 JAPAN: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 405
TABLE 666 JAPAN: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 406
TABLE 667 JAPAN: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 406
TABLE 668 JAPAN: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 406
TABLE 669 AUSTRALIA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 407
TABLE 670 AUSTRALIA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,
BY PHASE, 2024–2031 (USD MILLION) 408
TABLE 671 AUSTRALIA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 408
TABLE 672 AUSTRALIA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,
2024–2031 (USD MILLION) 408
TABLE 673 AUSTRALIA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,
2024–2031 (USD MILLION) 409
TABLE 674 AUSTRALIA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,
2024–2031 (USD MILLION) 409
TABLE 675 AUSTRALIA: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 409
TABLE 676 AUSTRALIA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 410
TABLE 677 AUSTRALIA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,
2024–2031 (USD MILLION) 410
TABLE 678 AUSTRALIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 411
TABLE 679 AUSTRALIA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 411
TABLE 680 AUSTRALIA: CRO SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 412
TABLE 681 AUSTRALIA: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 412
TABLE 682 AUSTRALIA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 412
TABLE 683 SOUTH KOREA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 413
TABLE 684 SOUTH KOREA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 414
TABLE 685 SOUTH KOREA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 414
TABLE 686 SOUTH KOREA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 414
TABLE 687 SOUTH KOREA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 415
TABLE 688 SOUTH KOREA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 415
TABLE 689 SOUTH KOREA: CRO SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 415
TABLE 690 SOUTH KOREA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 416
TABLE 691 SOUTH KOREA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,
2024–2031 (USD MILLION) 416
TABLE 692 SOUTH KOREA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 417
TABLE 693 SOUTH KOREA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 417
TABLE 694 SOUTH KOREA: CRO SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 418
TABLE 695 SOUTH KOREA: CRO SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 418
TABLE 696 SOUTH KOREA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 418
TABLE 697 REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 419
TABLE 698 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 420
TABLE 699 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 420
TABLE 700 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR PRECLINICAL SERVICES,
BY TYPE, 2024–2031 (USD MILLION) 420
TABLE 701 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR LABORATORY SERVICES,
BY TYPE, 2024–2031 (USD MILLION) 421
TABLE 702 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR ANALYTICAL TESTING,
BY TYPE, 2024–2031 (USD MILLION) 421
TABLE 703 REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 421
TABLE 704 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 422
TABLE 705 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 422
TABLE 706 REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 423
TABLE 707 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 423
TABLE 708 REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 424
TABLE 709 REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 424
TABLE 710 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 424
TABLE 711 LATIN AMERICA: CRO SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 425
TABLE 712 LATIN AMERICA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 425
TABLE 713 LATIN AMERICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,
BY PHASE, 2024–2031 (USD MILLION) 426
TABLE 714 LATIN AMERICA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 426
TABLE 715 LATIN AMERICA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 426
TABLE 716 LATIN AMERICA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 427
TABLE 717 LATIN AMERICA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 427
TABLE 718 LATIN AMERICA: CRO SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 427
TABLE 719 LATIN AMERICA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 428
TABLE 720 LATIN AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,
2024–2031 (USD MILLION) 428
TABLE 721 LATIN AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 429
TABLE 722 LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 429
TABLE 723 LATIN AMERICA: CRO SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 430
TABLE 724 LATIN AMERICA: CRO SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 430
TABLE 725 LATIN AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 430
TABLE 726 BRAZIL: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 431
TABLE 727 BRAZIL: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 431
TABLE 728 BRAZIL: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES,
BY TYPE, 2024–2031 (USD MILLION) 432
TABLE 729 BRAZIL: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,
2024–2031 (USD MILLION) 432
TABLE 730 BRAZIL: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,
2024–2031 (USD MILLION) 432
TABLE 731 BRAZIL: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,
2024–2031 (USD MILLION) 433
TABLE 732 BRAZIL: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 433
TABLE 733 BRAZIL: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 433
TABLE 734 BRAZIL: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,
2024–2031 (USD MILLION) 434
TABLE 735 BRAZIL: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 434
TABLE 736 BRAZIL: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 435
TABLE 737 BRAZIL: CRO SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 435
TABLE 738 BRAZIL: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 435
TABLE 739 BRAZIL: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 436
TABLE 740 MEXICO: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 436
TABLE 741 MEXICO: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 437
TABLE 742 MEXICO: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES,
BY TYPE, 2024–2031 (USD MILLION) 437
TABLE 743 MEXICO: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,
2024–2031 (USD MILLION) 437
TABLE 744 MEXICO: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,
2024–2031 (USD MILLION) 438
TABLE 745 MEXICO: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,
2024–2031 (USD MILLION) 438
TABLE 746 MEXICO: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 438
TABLE 747 MEXICO: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 439
TABLE 748 MEXICO: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,
2024–2031 (USD MILLION) 439
TABLE 749 MEXICO: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 440
TABLE 750 MEXICO: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 440
TABLE 751 MEXICO: CRO SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 441
TABLE 752 MEXICO: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 441
TABLE 753 MEXICO: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 441
TABLE 754 REST OF LATIN AMERICA: CRO SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 442
TABLE 755 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 442
TABLE 756 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 443
TABLE 757 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES,
BY TYPE, 2024–2031 (USD MILLION) 443
TABLE 758 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR LABORATORY SERVICES,
BY TYPE, 2024–2031 (USD MILLION) 443
TABLE 759 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR ANALYTICAL TESTING,
BY TYPE, 2024–2031 (USD MILLION) 444
TABLE 760 REST OF LATIN AMERICA: CRO SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 444
TABLE 761 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 444
TABLE 762 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 445
TABLE 763 REST OF LATIN AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 445
TABLE 764 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 446
TABLE 765 REST OF LATIN AMERICA: CRO SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 446
TABLE 766 REST OF LATIN AMERICA: CRO SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 446
TABLE 767 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 447
TABLE 768 MIDDLE EAST: CRO SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 447
TABLE 769 MIDDLE EAST: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 448
TABLE 770 MIDDLE EAST: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,
BY PHASE, 2024–2031 (USD MILLION) 448
TABLE 771 MIDDLE EAST: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 448
TABLE 772 MIDDLE EAST: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 449
TABLE 773 MIDDLE EAST: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 449
TABLE 774 MIDDLE EAST: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,
2024–2031 (USD MILLION) 449
TABLE 775 MIDDLE EAST: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 450
TABLE 776 MIDDLE EAST: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 450
TABLE 777 MIDDLE EAST: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,
2024–2031 (USD MILLION) 450
TABLE 778 MIDDLE EAST: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 451
TABLE 779 MIDDLE EAST: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 451
TABLE 780 MIDDLE EAST: CRO SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 452
TABLE 781 MIDDLE EAST: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 452
TABLE 782 MIDDLE EAST: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 452
TABLE 783 GCC COUNTRIES: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 453
TABLE 784 GCC COUNTRIES: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 453
TABLE 785 GCC COUNTRIES: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 453
TABLE 786 GCC COUNTRIES: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 454
TABLE 787 GCC COUNTRIES: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 454
TABLE 788 GCC COUNTRIES: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 454
TABLE 789 GCC COUNTRIES: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 455
TABLE 790 GCC COUNTRIES: CRO SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 455
TABLE 791 GCC COUNTRIES: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 455
TABLE 792 GCC COUNTRIES: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,
2024–2031 (USD MILLION) 456
TABLE 793 GCC COUNTRIES: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 456
TABLE 794 GCC COUNTRIES: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 457
TABLE 795 GCC COUNTRIES: CRO SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 457
TABLE 796 GCC COUNTRIES: CRO SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 457
TABLE 797 GCC COUNTRIES: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 458
TABLE 798 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 458
TABLE 799 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 459
TABLE 800 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 459
TABLE 801 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 459
TABLE 802 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 460
TABLE 803 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 460
TABLE 804 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 460
TABLE 805 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR BIOLOGICS,
BY TYPE, 2024–2031 (USD MILLION) 461
TABLE 806 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR BIOSIMILARS,
BY TYPE, 2024–2031 (USD MILLION) 461
TABLE 807 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 462
TABLE 808 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR ONCOLOGY,
BY TYPE, 2024–2031 (USD MILLION) 462
TABLE 809 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 463
TABLE 810 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 463
TABLE 811 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE,
2024–2031 (USD MILLION) 463
TABLE 812 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 464
TABLE 813 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 465
TABLE 814 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 465
TABLE 815 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 465
TABLE 816 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 466
TABLE 817 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 466
TABLE 818 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 466
TABLE 819 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 467
TABLE 820 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR BIOSIMILARS,
BY TYPE, 2024–2031 (USD MILLION) 467
TABLE 821 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 468
TABLE 822 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 468
TABLE 823 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 469
TABLE 824 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 469
TABLE 825 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 469
TABLE 826 REST OF GCC COUNTRIES: CRO SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 470
TABLE 827 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 470
TABLE 828 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 471
TABLE 829 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION) 471
TABLE 830 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION) 471
TABLE 831 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR ANALYTICAL TESTING,
BY TYPE, 2024–2031 (USD MILLION) 472
TABLE 832 REST OF GCC COUNTRIES: CRO SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 472
TABLE 833 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 472
TABLE 834 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 473
TABLE 835 REST OF GCC COUNTRIES: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 473
TABLE 836 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 474
TABLE 837 REST OF GCC COUNTRIES: CRO SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 474
TABLE 838 REST OF GCC COUNTRIES: CRO SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 474
TABLE 839 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 475
TABLE 840 REST OF MIDDLE EAST: CRO SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 475
TABLE 841 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 476
TABLE 842 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 476
TABLE 843 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR PRECLINICAL SERVICES,
BY TYPE, 2024–2031 (USD MILLION) 476
TABLE 844 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR LABORATORY SERVICES,
BY TYPE, 2024–2031 (USD MILLION) 477
TABLE 845 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR ANALYTICAL TESTING,
BY TYPE, 2024–2031 (USD MILLION) 477
TABLE 846 REST OF MIDDLE EAST: CRO SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 477
TABLE 847 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 478
TABLE 848 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION) 478
TABLE 849 REST OF MIDDLE EAST: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 479
TABLE 850 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 479
TABLE 851 REST OF MIDDLE EAST: CRO SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 480
TABLE 852 REST OF MIDDLE EAST: CRO SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 480
TABLE 853 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 480
TABLE 854 AFRICA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 481
TABLE 855 AFRICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION) 481
TABLE 856 AFRICA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES,
BY TYPE, 2024–2031 (USD MILLION) 482
TABLE 857 AFRICA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,
2024–2031 (USD MILLION) 482
TABLE 858 AFRICA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,
2024–2031 (USD MILLION) 482
TABLE 859 AFRICA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,
2024–2031 (USD MILLION) 483
TABLE 860 AFRICA: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 483
TABLE 861 AFRICA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 483
TABLE 862 AFRICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,
2024–2031 (USD MILLION) 484
TABLE 863 AFRICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 484
TABLE 864 AFRICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 485
TABLE 865 AFRICA: CRO SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 485
TABLE 866 AFRICA: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 485
TABLE 867 AFRICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 486
TABLE 868 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN CRO SERVICES MARKET, JANUARY 2023-MARCH 2026 487
TABLE 869 CRO SERVICES MARKET: DEGREE OF COMPETITION 490
TABLE 870 CRO SERVICES MARKET: REGION FOOTPRINT 495
TABLE 871 CRO SERVICES MARKET: TYPE FOOTPRINT 496
TABLE 872 CRO SERVICES MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 499
TABLE 873 CRO SERVICES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SME PLAYERS, BY TYPE AND REGION 500
TABLE 874 CRO SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2023–MARCH 2026 503
TABLE 875 CRO SERVICES MARKET: DEALS, JANUARY 2023–MARCH 2026 504
TABLE 876 CRO SERVICES MARKET: EXPANSIONS, JANUARY 2023–MARCH 2026 505
TABLE 877 IQVIA INC.: COMPANY OVERVIEW 506
TABLE 878 IQVIA INC.: SERVICES/SOLUTIONS OFFERED 507
TABLE 879 IQVIA INC.: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–MARCH 2026 509
TABLE 880 IQVIA INC.: DEALS, JANUARY 2023–MARCH 2026 510
TABLE 881 ICON PLC: COMPANY OVERVIEW 513
TABLE 882 ICON PLC.: SERVICES/SOLUTIONS OFFERED 514
TABLE 883 ICON PLC.: SERVICE LAUNCHES, JANUARY 2023–MARCH 2026 516
TABLE 884 ICON PLC: DEALS, JANUARY 2023–MARCH 2026 516
TABLE 885 ICON PLC.: EXPANSIONS, JANUARY 2023–MARCH 2026 517
TABLE 886 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 518
TABLE 887 THERMO FISHER SCIENTIFIC INC.: SERVICES/SOLUTIONS OFFERED 519
TABLE 888 THERMO FISHER SCIENTIFIC, INC.: SERVICE LAUNCHES,
JANUARY 2023–MARCH 2026 521
TABLE 889 THERMO FISHER SCIENTIFIC, INC.: DEALS, JANUARY 2021–APRIL 2026 522
TABLE 890 THERMO FISHER SCIENTIFIC, INC.: EXPANSIONS, JANUARY 2023–MARCH 2026 523
TABLE 891 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW 525
TABLE 892 LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICES/SOLUTIONS OFFERED 526
TABLE 893 LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICE LAUNCHES, JANUARY 2023–MARCH 2026 528
TABLE 894 LABORATORY CORPORATION OF AMERICA HOLDINGS: DEALS,
JANUARY 2023–MARCH 2026 528
TABLE 895 LABORATORY CORPORATION OF AMERICA HOLDINGS: EXPANSIONS, JANUARY 2023–MARCH 2026 529
TABLE 896 LABORATORY CORPORATION OF AMERICA HOLDINGS: OTHER DEVELOPMENTS, JANUARY 2023–MARCH 2026 530
TABLE 897 FORTREA, INC.: BUSINESS OVERVIEW 531
TABLE 898 FORTREA, INC.: SERVICES/SOLUTIONS OFFERED 532
TABLE 899 FORTREA, INC.: SERVICE LAUNCHES, JANUARY 2023–MARCH 2026 534
TABLE 900 FORTREA, INC.: DEALS, JANUARY 2023–MARCH 2026 535
TABLE 901 FORTREA, INC.: EXPANSIONS, JANUARY 2023–MARCH 2026 536
TABLE 902 FORTREA, INC.: OTHER DEVELOPMENTS, JANUARY 2023–MARCH 2026 536
TABLE 903 SYNEOS HEALTH: COMPANY OVERVIEW 537
TABLE 904 SYNEOS HEALTH: SERVICES/SOLUTIONS OFFERED 537
TABLE 905 SYNEOS HEALTH: SERVICE LAUNCHES, JANUARY 2023–MARCH 2026 539
TABLE 906 SYNEOS HEALTH: DEALS, JANUARY 2023–MARCH 2026 539
TABLE 907 WUXI APPTEC: COMPANY OVERVIEW 541
TABLE 908 WUXI APPTEC: SERVICES/SOLUTIONS OFFERED 542
TABLE 909 WUXI APPTEC: EXPANSIONS, JANUARY 2023–MARCH 2026 544
TABLE 910 WUXI APPTEC: OTHER DEVELOPMENTS, JANUARY 2023–MARCH 2026 545
TABLE 911 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW 546
TABLE 912 CHARLES RIVER LABORATORIES: SERVICES/SOLUTIONS OFFERED 547
TABLE 913 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2023–MARCH 2026 548
TABLE 914 PAREXEL INTERNATIONAL CORPORATION: COMPANY OVERVIEW 550
TABLE 915 PAREXEL INTERNATIONAL CORPORATION: SERVICES/SOLUTIONS OFFERED 551
TABLE 916 PAREXEL INTERNATIONAL CORPORATION: DEALS, JANUARY 2023–MARCH 2026 552
TABLE 917 PAREXEL INTERNATIONAL CORPORATION: EXPANSIONS,
JANUARY 2023–MARCH 2026 553
TABLE 918 PHARMARON: COMPANY OVERVIEW 554
TABLE 919 PHARMARON: SERVICES/SOLUTIONS OFFERED 555
TABLE 920 MEDPACE: COMPANY OVERVIEW 557
TABLE 921 MEDPACE: SERVICES/SOLUTIONS OFFERED 558
TABLE 922 SGS SA: COMPANY OVERVIEW 560
TABLE 923 SGS SA: SERVICES/SOLUTIONS OFFERED 561
TABLE 924 SGS SA: DEALS, JANUARY 2023–MARCH 2026 563
TABLE 925 FRONTAGE LABS: COMPANY OVERVIEW 564
TABLE 926 FRONTAGE LABS: SERVICES/SOLUTIONS OFFERED 565
TABLE 927 FRONTAGE LABS: DEALS, JANUARY 2023–MARCH 2026 567
TABLE 928 FRONTAGE LABS: OTHER DEVELOPMENTS, JANUARY 2023–MARCH 2026 568
TABLE 929 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 569
TABLE 930 EUROFINS SCIENTIFIC: SERVICES/SOLUTIONS OFFERED 570
TABLE 931 TIGERMED: COMPANY OVERVIEW 572
TABLE 932 TIGERMED: SERVICES OFFERED 573
TABLE 933 TIGERMED: PRODUCT/ SERVICE APPROVALS, JANUARY 2023–MARCH 2026 575
TABLE 934 TIGERMED: DEALS, JANUARY 2023–MARCH 2026 575
TABLE 935 PSI CRO AG: COMPANY OVERVIEW 577
TABLE 936 PSI CRO AG: SERVICES/SOLUTIONS OFFERED 577
TABLE 937 PSI CRO AG: SERVICE LAUNCHES, JANUARY 2023–MARCH 2026 578
TABLE 938 PSI CRO AG: DEALS, JANUARY 2023–MARCH 2026 578
TABLE 939 PSI CRO AG: EXPANSIONS, JANUARY 2023–MARCH 2026 579
TABLE 940 BIOAGILE: COMPANY OVERVIEW 580
TABLE 941 BIOAGILE: SERVICES/SOLUTIONS OFFERED 580
TABLE 942 FIRMA CLINICAL RESEARCH: COMPANY OVERVIEW 582
TABLE 943 FIRMA CLINICAL RESEARCH: SERVICES/SOLUTIONS OFFERED 582
TABLE 944 ACCULAB LIFE SCIENCES: COMPANY OVERVIEW 583
TABLE 945 ACCULAB LIFE SCIENCES: SERVICES/SOLUTIONS OFFERED 583
TABLE 946 NOVOTECH: COMPANY OVERVIEW 584
TABLE 947 NOVOTECH: SERVICES/SOLUTIONS OFFERED 584
TABLE 948 NOVOTECH HEALTH HOLDINGS: DEALS, JANUARY 2023–MARCH 2026 586
TABLE 949 LINICAL: COMPANY OVERVIEW 588
TABLE 950 LINICAL: SERVICES/SOLUTIONS OFFERED 588
TABLE 951 LINICAL: EXPANSIONS, JANUARY 2023–MARCH 2026 589
TABLE 952 ADVANCED CLINICAL: COMPANY OVERVIEW 590
TABLE 953 ADVANCED CLINICAL: SERVICES/SOLUTIONS OFFERED 590
TABLE 954 ADVANCED CLINICAL: DEALS, JANUARY 2023–MARCH 2026 591
TABLE 955 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 607
TABLE 956 CRO SERVICES MARKET: RISK ANALYSIS 610

LIST OF FIGURES

FIGURE 1 MARKET SCENARIO 63
FIGURE 2 GLOBAL CRO SERVICES MARKET, 2024–2031 64
FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CRO SERVICES MARKET, 2023–2026 64
FIGURE 4 DISRUPTIONS INFLUENCING THE GROWTH OF THE CRO SERVICES MARKET 65
FIGURE 5 HIGH-GROWTH SEGMENTS IN CRO SERVICES MARKET, 2026–2031 66
FIGURE 6 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN THE CRO SERVICES MARKET, IN TERMS OF VALUE, DURING THE FORECAST PERIOD 67
FIGURE 7 INCREASING SIZE OF THE CLINICAL DEVELOPMENT PIPELINE TO PROPEL MARKET GROWTH 69
FIGURE 8 US AND SMALL MOLECULES SEGMENT COMMANDED LARGEST
MARKET SHARES IN 2025 70
FIGURE 9 CHINA TO REGISTER HIGHER CAGR DURING FORECAST PERIOD 71
FIGURE 10 DRIVERS, OPPORTUNITIES, AND CHALLENGES: CRO SERVICES MARKET 72
FIGURE 11 ACTIVE PHARMACEUTICAL PIPELINE, 2015–2026 76
FIGURE 12 PORTER’S FIVE FORCES ANALYSIS: CRO SERVICES MARKET 83
FIGURE 13 CRO SERVICES MARKET: VALUE CHAIN ANALYSIS 86
FIGURE 14 CRO SERVICES MARKET: ECOSYSTEM ANALYSIS 88
FIGURE 15 INDICATIVE PRICING ANALYSIS (PER STUDY), BY REGION, 2025 (USD MILLION) 91
FIGURE 16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS IN CRO SERVICES MARKET 92
FIGURE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CRO SERVICES,
BY MODALITY 115
FIGURE 18 KEY BUYING CRITERIA FOR CRO SERVICES ACROSS END USERS 116
FIGURE 19 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2024 VS. 2025 122
FIGURE 20 CANCER (%) AS A PROPORTION OF PIPELINE IN DEVELOPMENT, 2013–2024 243
FIGURE 21 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000–2045 (MILLION) 273
FIGURE 22 ANNUAL DRUG APPROVALS BY FDA CENTER FOR DRUG EVALUATION AND RESEARCH, 2013–2025 305
FIGURE 23 R&D SPENDING OF PHRMA MEMBER COMPANIES, 2013–2024 305
FIGURE 24 US FDA DE NOVO MEDICAL DEVICE APPROVALS, 2012–2024 315
FIGURE 25 NORTH AMERICA: CRO SERVICES MARKET SNAPSHOT 324
FIGURE 26 GLOBAL DISTRIBUTION OF R&D COMPANIES, JANUARY 2025 VS. JANUARY 2026 331
FIGURE 27 ASIA PACIFIC: CRO SERVICES MARKET SNAPSHOT 383
FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET (2021–2025) 489
FIGURE 29 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET (2025) 490
FIGURE 30 CRO SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 493
FIGURE 31 CRO SERVICES MARKET: COMPANY FOOTPRINT 494
FIGURE 32 CRO SERVICES MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2025 498
FIGURE 33 EV/EBITDA OF KEY VENDORS 501
FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 501
FIGURE 35 CRO SERVICES MARKET: SERVICE COMPARATIVE ANALYSIS 502
FIGURE 36 IQVIA INC.: COMPANY SNAPSHOT (2025) 507
FIGURE 37 ICON PLC: COMPANY SNAPSHOT (2024) 514
FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 519
FIGURE 39 LABORATORY CORPORATION OF AMERICA HOLDINGS:
COMPANY SNAPSHOT (2025) 526
FIGURE 40 FORTREA, INC.: COMPANY SNAPSHOT 531
FIGURE 41 WUXI APPTEC: COMPANY SNAPSHOT 542
FIGURE 42 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT 547
FIGURE 43 PHARMARON: COMPANY SNAPSHOT 555
FIGURE 44 MEDPACE: COMPANY SNAPSHOT 558
FIGURE 45 SGS SA: COMPANY SNAPSHOT 561
FIGURE 46 FRONTAGE LABS: COMPANY SNAPSHOT 565
FIGURE 47 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT 570
FIGURE 48 TIGERMED: COMPANY SNAPSHOT 573
FIGURE 49 CRO SERVICES MARKET: RESEARCH DESIGN 598
FIGURE 50 CRO SERVICES MARKET: BREAKDOWN OF PRIMARIES
(DEMAND- AND SUPPLY-SIDE PARTICIPANTS) 600
FIGURE 51 GLOBAL CRO SERVICES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025 601
FIGURE 52 GLOBAL CRO SERVICES MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH), 2025 602
FIGURE 53 ILLUSTRATIVE EXAMPLE OF IQVIA INC.: REVENUE SHARE ANALYSIS, 2025 603
FIGURE 54 CRO SERVICES MARKET SIZE VALIDATION FROM PRIMARY SOURCES 604
FIGURE 55 TOP-DOWN APPROACH 604
FIGURE 56 GLOBAL CRO SERVICES MARKET: CAGR PROJECTIONS, 2026–2031 606
FIGURE 57 CRO SERVICES MARKET: DATA TRIANGULATION METHODOLOGY 608

---

---